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1. Introduction 
1.1. Membrane proteins 
In living systems the membrane-associated proteins play essential roles in the maintenance of 
the normal life functions. Membrane proteins have various functions as there are membrane 
receptors, transport proteins, enzymes and cell adhesion molecules among them.1-8 Typically 
50% of the membrane mass is protein, but this ratio varies between 25% and 75% depending 
on the type of the membrane. The importance of membrane proteins is also indicated by the 
fact that 20-30% of the genes in most organisms encodes membrane proteins.9 
Membrane proteins are associated with lipid bilayers in different ways, and they can be 
classified as integral, peripheral and lipid-anchored proteins.10-12 Integral membrane proteins 
are persistently bound to cell membrane and transmembrane proteins spanned across the 
membrane at least once.13 This type of proteins occurs as α-helix bundle proteins in all cell 
membrane and β-barrel proteins which occur in the membrane bilayer of bacteria, 
mitochondria and chloroplasts. Peripheral membrane proteins can temporarily associate with 
the cell membrane (Figure 1) or with integral membrane proteins via non-covalent 
hydrophobic-hydrophobic interactions.14 Furthermore, membrane anchoring via a lipid moiety 
that is covalently linked to the protein is also frequent.12 The membrane anchors of these 
lipoproteins are added to the prematured protein in co- or posttranslational lipidation 
processes, and these lipid modifications modulate the membrane affinity, localization and 
trafficking of the protein.15 
 
Figure 1. Representative section of the plasma membrane. 
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Figure 2. Typical lipidated proteins. 
The most frequent lipid modifications include S-prenylation and S-palmitoylation of Cys 
residues, N-myristoylation of N-terminal Gly residues (Figure 2) and C-terminal amidation 
with glycosylphosphatidylinositol (GPI) glycolipids (Figure 3).3, 16-20 The GPI anchor 
molecule is a glycosylated phosphatidylinositol where the glycan core consists of a 
glucosamine and three mannoses, and also contains a terminal ethanolamine phosphate. 
The different topology results in functional differences between integral and anchored 
membrane proteins. The integral membrane proteins have hydrophobic polypeptide region(s) 
which can span the lipid bilayer, and in general the major part of these proteins is located in 
the membrane bilayer. Consequently, these proteins connect the extra- and intracellular space, 
and thus, they can transmit environmental information or stimuli across the plasma 
membrane. In contrast, the polypeptide chain of the membrane anchored proteins is located 
outside the lipid bilayer and only a tiny portion of the sequence can be found in the lipid 
bilayer. 
1.2. Glycosylphosphatidylinositol-anchored proteins 
The amidation of a protein C-terminus with a GPI glycolipid results in proteins that are 
tethered to the extracellular leaflet of the cell membrane.21-23 The GPI anchor is widespread 
throughout eukaryotes and GPI-anchored proteins (GPI-APs) are presented in all major cell 
types and tissues. More than 150 human proteins with various functions contain a GPI anchor: 
enzymes, receptors, complement regulation proteins, antigens or adhesion molecules.24, 25 The 
size of these proteins varies between the 12 amino acid glycopeptide CD52 and the 175 kDa 
protein CDw109.26 Beyond the normal physiological functions, GPI-APs are associated with a 
range of diseases including paroxysmal nocturnal hemoglobinuria, prion diseases, 
carcinogenesis and sleeping sickness and the pathobiology of trypanosomal parasites.24, 27-29 
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The important functional role of the GPI-APs is further evidenced by the embryonic lethality 
of the GPI-deficient mice.30 
The GPI glycolipids have the conserved Man(α1-2)Man(α1-6)Man(α1-4)GlcN(α1-
6)myoIno glycan core and variations arise in the substitution pattern and in the number and 
type of the lipid moiety (Figure 3).31, 32 The glycan can be substituted with 
phosphoethanolamine, sialic acid or other carbohydrates.33-43 The most frequent modification 
on the Man I residue is another mannose, while a phosphoethanolamine can be linked to Man 
II or Man III. In GPI-APs the phosphoethanolamine attached to Man III is N-acylated with the 
C-terminal carboxyl group of the protein. Furthermore, N-acetylgalactoseamine-containing 
oligosaccharides can also be attached to Man III.23 The identified lipids include 
diacylglycerols, alkylacylglycerols or ceramides with different length of alkyl chains between 
14 and 28 carbons.43 There are species of GPI anchors where the 2-hydroxyl group of the 
inositol ring is O-acylated with an additional fatty acid, such as palmitic acid.43 This feature 
makes these GPI anchors resistant to phosphatidylinositol phospholipase C (PI-PLC)-
catalysed hydrolysis.21, 44 This cleavage mechanism is involved in GPI-AP-mediated cellular 
communications or signal transduction.44  
 
Figure 3.  General structure of the GPI anchors. 
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The lipid part of the mammalian GPIs is phosphatidylinositol with stearyl chains, therefore 
the GPI-APs are able to temporarily associate with sphingolipid- and cholesterol-rich 
membrane microdomains, i.e. lipid rafts.21, 32, 44-48 Cholesterol is an essential component of the 
lipid rafts evidenced by the observation that the depletion of cholesterol causes disruption of 
the rafts.49 Furthermore, the lipid raft association of the GPI-APs could be abrogated by 
cholesterol depletion of the cell membrane and by replacing the GPI moiety with a 
transmembrane anchor.50 The accumulation of the GPI-APs in the less fluidic lipid rafts may 
serve as platforms for diverse cellular functions (e.g. signal transduction) via optimizing 
protein-protein interactions.51, 52 However, the enrichment of GPI-APs in rafts is a matter of 
debate, because this process might depend on both the GPI anchor species and the attached 
protein.49, 53, 50 There are evidences for the presence of GPI-APs in Triton X-100 insoluble 
membrane fractions that is lipid rafts.49, 53 It was also reported that cell surface GPI-APs were 
present as monomers and 20-40% of GPI-APs were present in cholesterol-sensitive lipid 
clusters containing up to four GPI-APs.50 
The only established role of the protein attached GPI anchors is to accomplish the 
membrane association of the protein. However, the complex structure and the energetically 
expensive biosynthesis of GPIs suggest further functions.21, 44 The GPI anchor might change 
the structure of the attached protein and this way it might transfer external signals through the 
lipid bilayer.23 The anchored proteins are positioned about 10-14 Å away from the membrane 
surface, and this distance and the flexibility of the glycan core allow the interaction of the 
proteins with the membrane.54 However, the details of such possible interactions between the 
protein and the cell membrane are unknown. A GPI molecule can keep connection between 
the extracellular environment and internal signaling molecules. If an antibody is cross-linked 
with GPI anchored proteins, cellular activation or inhibition signals will be started through 
Ca2+ fluxes, protein tyrosine phosphorylation or cytokine secretion. These effects are not 
observed when the GPI anchor is replaced with a transmembrane domain.55, 56 In other GPI-
AP-related signal transduction the GPI-APs are associated with transmembrane signal 
transduction partners, such as protein tyrosine kinases, integrins and heterotrimeric GTP-
binding proteins.52, 55, 56 But these biological functions of the GPIs are rather unknown in 
details, partly because the structural complexity of the GPIs restricts the preparation of GPI-
AP derivatives for systematic studies.23 The influence of GPIs has also been supposed in 
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either endocytosis or in the distribution between the apical and basolateral cell surface.57, 58 
The best characterized endocytosis is the clathrin-dependent endocytosis which requires a 
cytoplasmic tail of the transmembrane protein. This tail is recognized by endocytic adaptor 
proteins which serve as a bridge between transmembrane protein and clathrin. GPI-APs are 
targeted for clathrin dependent endocytosis probably with their interactions with 
transmembrane proteins because their cytoplasmic tail is lacking.59, 60 
The absence of their association with transmembrane proteins supposed another endocytic 
mechanism which depends on the GPI anchor itself. The raft regions cannot undergo clathrin-
mediated endocytosis because the highly ordered nature of saturated lipids in rafts will not 
permit the tight curvature of the membrane required for the formation of clathrin-coated pits.61 
In the context of targeted protein delivery, a unique feature of the GPI-APs is that after 
isolation they spontaneously reintegrate into lipid membranes of enveloped viruses or live 
cells with the retention of the biological function.62-76 Since exogenously added GPI-APs 
retained the characteristics and functions of the expressed GPI-APs, this method can be 
exploited for structural and functional studies of GPI-APs and for delivery of 
pharmacologically active proteins. Furthermore, GPI-APs could be presented with this 
process by cells that cannot synthesize their own GPI-APs under normal conditions. 
1.3. Prion protein 
The prion protein (PrP) is a cell surface GPI-anchored glycoprotein77, expressed by a variety 
of cell types, but particularly abundant in neurons. The PrP is associated with transmissible 
spongiform encephalopathies (TSEs), also known as prion diseases, a group of 
neurodegenerative disorders. These encephalopathies include scrapie in sheep, bovine 
spongiform encephalopathy or “mad cow disease” in cattle, chronic wasting disease in deer 
and elk, as well as Creutzfeldt-Jakob disease in humans.61, 78 These diseases are similar to 
amyloidosis and Alzheimer’s syndrome where a host-derived protein is misfolded and persists 
in an aggregated form that may damage nearby cells.79 Besides the similarity, there are 
important differences between them. In amyloidosis the amyloid deposits are directly 
pathogenic, in Alzheimer’s diseases pre-amyloid forms may be the major neuropathogenic 
form.80-82 In prion diseases the host protein is involved in misfolding and amyloid formation, 
and PrP is necessary for replication and infectivity of the disease.83, 84 The fundamental 
molecular event behind the serious damage of the central nervous system is the  
6 
 
 
Figure 4. Structure of the prematured murine PrPC. (23-28) polybasic region, (51-91) copper binding 
octapetide region, (106-126) hydrophobic neurotoxic domain. This figure is a reproduction of the work of Taylor 
and Hooper.61 
conformational conversion of the metastable cellular normal protease-sensitive prion protein 
(PrPC) into the infectious, protease-resistant pathogenic isoform (PrPSc).61 If this protease-
resistant GPI anchored PrPSc is formed and propagated, it will result in insoluble protein 
plaques on neurons. The formation of these plaques might interfere with the normal PrP 
signaling function, leading to neuronal death. PrP is expressed as a GPI-anchored cell surface 
glycoprotein.77 The human PrnP gene encodes a precursor protein with 253 amino acids, and 
the N-terminal 22-mer signal sequence directs the protein to the rough endoplasmic reticulum, 
then the C-terminal 23-mer peptide is removed and the new C-terminus (Ser230) is amidated 
with a GPI followed by the cleavage of the N-terminal signal sequence (Figure 4).77 These 
maturation events yield a GPI-anchored PrPC of 208 amino acids, which is transferred to the 
extracellular space and it remains attached to the exterior leaflet of the cell membrane. PrPC 
has a folded C-terminal domain with three -helices and an unstructured N-terminal domain.85 
Although the exact 3D structure of PrPSc is not known, there is an increased β-sheet content 
replacing the normal α-helical areas of PrPC.86 
Both isoforms possess a disulfide bond between Cys179 and Cys214 linking the -helices 2 
and 3,87 and they can be di-, mono- or nonglycosylated at Asn180 and Asn196 with more than 
50 different carbohydrate species. The C-terminal GPI anchor plays a crucial role in the prion 
diseases, because the anchorless PrP does not lead to pathological conditions. It was proved 
by the combined expression of the anchorless and the wild-type PrP, when accelerated clinical 
scrapie was produced.79, 88 Furthermore, replacing the C-terminal GPI addition sequence of 
PrP to a transmembrane or a cytosolic domain of non-raft proteins also prevented the 
formation of PrPSc.89, 90 Additionally, in vitro experiments with raft preparations from PrP- 
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Figure 5. A possible mechanism of PrPSc propagated conformational conversion of PrPC that results in 
neurotoxicity.61 
infected and non-infected cells point to the fact that co-localization of PrPC and PrPSc is a 
prerequisite for the conversion of PrPC to PrPSc.91-94 The importance of lipid raft association in 
the conformational changes of PrPC to PrPSc is further indicated by the finding that the 
depletion of cellular cholesterol diminished the formation of PrPSc.89, 95, 96 The GPI anchor 
also plays an important role in prion pathogenesis via the plaque formation of PrPSc which 
might interfere with the normal prion signaling and can cause neuronal death.79, 88 
In contrast, Priola and coworkers evidenced that the GPI anchor is not essential for the 
formation of PrPSc, but it is important in the amplification and spread of prion infectivity.97 
Even though the membrane attachment seems to be crucial for the pathogenesis, previous 
studies have only been performed with recombinant, soluble PrP lacking any membrane 
anchor98, 99 or with PrP having anchor mimics structurally not related to the native GPI 
anchor.93, 94, 100, 101 The structural consequences of the membrane association of these PrP 
derivatives have not been investigated on cellular or model membranes. 
According to these observations the following mechanism was hypothesized for the prion 
pathogenesis. The GPI anchored PrPC is clustered in lipid rafts and transduces neuroprotective 
signals into the cell.88 Infectious PrPSc is inserted into the target cell membrane alongside the 
PrPC in the rafts.88 Conversion of the PrPC to PrPSc may affect signaling events involving 
PrPC, leading to neurotoxicity and cell death (Figure 5).88 
1.4. Synthetic glycosylphosphatidylinositol analogues 
The investigation of the functions of GPIs is challenging, partly because multimilligram 
quantities of native GPI anchors are hardly available.23 Furthermore, the biosynthetic enzymes 
are not well characterized, and specific inhibitors are not available for the ca. 20 enzymes 
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responsible for the GPI synthesis. The extraction of GPI-APs from cell membrane has 
inherent difficulties because they exist in heterogeneous mixtures with variation in their 
glycan core and lipid moiety.26, 35, 37, 102 A possible solution is the chemical synthesis of 
representative diacylglycerophosphoinositolglycan species, but currently these methods are 
complicated and not well applicable for protein anchoring.103, 104 An example of this problem 
is to set up appropriate experiments for answering how important the GPI-anchoring is in the 
basic PrPSc replication process. The demand for membrane associated PrP analogues inspired 
huge efforts to prepare semisynthetic lipo-PrP derivatives (Figure 6). Because the full length 
PrP is highly aggregation prone, sometimes the C-terminal folded fragment or even shorter 
sequences were used to conjugate with the lipophilic anchors.100, 101, 105, 106 Beyond, the 
fluorescent protein GFP was also used to demonstrate the membrane anchoring properties of 
such synthetic lipids.93, 94, 100, 101, 103, 105-109 It was found that the removal of the carbohydrate 
moiety or its truncation can retain the anchoring function of the GPIs.110 Most of these 
synthetic anchors act solely as membrane anchoring devices without any carbohydrate unit, 
but there are analogues where the GPI mimetics contain one or two mannoses or an 
oligo(ethylene glycol) linker with a length similar to the glycan core of native GPIs. The 
membrane association features could be successfully investigated with these simple synthetic 
GPI anchor analogues. The GFP – GPI mimic conjugates were incorporated into model lipid 
bilayers or cell membranes and it was found that the lipo-GFP derivatives trafficked to 
 
Figure 6.  Semisynthetic GPI anchor mimetics attached to PrP or GFP.93, 94, 100, 101, 105-107 
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recycling endosomes similarly to GFP bearing a native GPI anchor.110 However, the deletion 
of the glycan core significantly altered the lateral diffusion kinetics of these lipoproteins in the 
plasma membrane.110 
Lipidation of proteins with GPI surrogates and the purification of the resulting 
lipoproteins are crucial steps in the semisynthesis of membrane-anchored proteins, because 
the proteins might lose their native structure and biological function.111 In this thesis a new 
series of protein membrane anchors applicable in aqueous solutions without denaturing the 
protein were designed, prepared and investigated in vitro. Fluorescent labelling of the GPI 
mimics was applied to achieve the microscopic monitoring of the cellular traffic of the 
anchors and their protein derivatives. 
Investigation of GPI mimics in the form of GFP conjugates can be used to evaluate that 
the membrane anchor is appropriate for anchoring attached proteins to the cell membrane.110 
However, these lipo-GFPs cannot represent the specific protein-membrane interactions of the 
investigated protein, e.g. PrP. When the fluorescent reporter protein is fused to the lipidated 
target protein, the reporter protein with a size comparable to that of the target protein might 
perturb the biophysical and biochemical characteristics of the investigated membrane-
anchored protein. In order to avoid these drawbacks, our concept is based on the application 
of a small molecule fluorophore in the lipid headgroup for the imaging of the membrane 
anchored protein. This way it does not interfere with the lipid chains of the cell membrane, 
and it has presumably minimal effect on protein – protein and protein – membrane 
interactions on the cell surface. The capturing of proteins to the synthetic anchors was a 
crucial point of previous studies to preserve the native protein fold. So it is very important to 
demonstrate a fast and chemoselective reaction between the designed anchors and proteins. 
This protein capturing functional group must be located on the upper part of the synthetic 
anchor for modeling the native GPI. 
In analogy with the spontaneous membrane integration property of GPI-APs, 
semisynthetic lipoproteins containing GPI anchor mimetic lipids can also be exogenously 
introduced into the cell membrane presumably with the retention of the protein structure and 
function. Since cholesterol prefers the interaction with sphingolipids in the cell membrane, it 
has the potential to target an attached protein to lipid rafts.47, 48 This lipid anchor is found in 
the matured Hh and Shh proteins of the hedgehog family as a C-terminal cholesteryl ester.112-
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115 Furthermore, in the case of a semisynthetic peptidyl cholesterol – Ras protein conjugate, 
cholesterol was reported to anchor the attached protein to the cell membrane.116 Other 
cholesterol derivatives, such as 3β-cholesterylamine and 3β-cholesterylcarbamate were also 
reported as membrane anchors of artificial membrane receptors.117-123 Further rationale behind 
the cholesterol-based anchoring of proteins is the fact that cholesterol depletion decreases the 
amount of GPI-APs on the cell surface, and abrogates the association of GPI-APs with lipid 
rafts50. The cholesterol “leg” and the fluorescent “headgroup” are linked by a flexible, 
hydrophilic oligo(ethylene glycol) linker that allows the protein to interact with the lipid 
bilayer, other cell surface proteins and with extracellular components. Furthermore, it is 
possible to examine the influence of membrane surface – protein distance and to optimize the 
hydrophobic/hydrophilic character of the anchor with the variation of linker length. 
1.5. Cell surface bioconjugation 
Sharples and Meldal have independently developed a Cu(I) catalyzed form of the Husigen’s 
1,3-dipolar cycloaddition (CuAAC)124, 125 that became applicable as a chemical ligation 
method in biological systems. This chemical transformation is characterized by high 
chemoselectivity and broad tolerance to diverse reaction condition and functional 
groups.23, 24, 126-129 In addition, as neither azide nor alkyne is generally present in 
biomolecules, they are bioorthogonal functional groups.129 In the early CuAAC reactions 1 
mM copper was applied that limited the biological applications because it resulted in 
considerable cell death.130 Cu(I) concentration below 500 μM, however, is tolerated by 
mammalian cells for 1 hour,83 and the effective Cu+ concentration is maintained by the in situ 
reduction of CuSO4 with sodium ascorbate (NaAsc).131 This way the CuAAC reaction can be 
widely used for capturing small molecules to proteins or living cells.83 There are some 
examples where the bioactivity of the resulting modified protein decreased after the CuAAC 
reaction.132-134 During the reaction the generated dehydroascorbate and other by-products can 
react with the amino and guanidino groups of Lys and Arg, respectively, that may causes 
protein aggregation.135, 136 The Cu(II)/NaAsc system generates reactive oxygen species (ROS) 
in the presence of O2 (Figure 7), which provides oxidative stress for biomolecules.135, 137-139 In 
order to facilitate this CuAAC reaction for biomolecules chelating ligands were developed to 
stabilize the Cu(I)-ion (Figure 8).127-129, 140-147 The application of these Cu(I)-ligands 
decreased the effective concentration of reducing agent and copper-salts, and also accelerated  
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Figure 7. Mechanism of CuAAC (A), reactive oxygen species production (B) and Cu(I) formation (C) by the 
NaAsc mediated CuSO4 reduction. 
the bioconjugation reaction and protected the biomolecules from the oxidation by 
ROS.127, 129, 148-150 Aminoguanidine, a carbonyl-capturing reagent is frequently used because it 
stabilizes proteins during CuAAC by avoiding the adverse effects of ascorbate and its by-
products.23 For bioorganic chemistry applications water-soluble accelerator ligands (e.g. 
tris(triazolylmethyl)amines) were developed.146, 151-153 When these ligand accelerated CuAAC 
reactions were used in vitro, live cells showed normal functions after the treatment evidencing 
their applicability in living systems.146, 151-153 The reaction time of CuAAC reaction with these 
accelerator ligands was optimized for 5-10 min, because in longer reaction time significant 
cell death was observed.146, 147, 151, 154 In Kennedy’s work L-histidine (His) was used as 
accelerator ligand that resulted in a two- to threefold slower reaction as compared to other 
ligands (e.g. BTTAA, BTTP), but the cytotoxicity was lower that makes the application of 
longer reaction time possible.154 It was also reported that cells tolerated the treatment with 
 
Figure 8.  CuAAC reaction accelerator ligands. 
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Figure 9. Cell surface CuAAC of a protein alkyne and a membrane incorporated azido-cholesterol. 
Cu(I) − His complex in the presence of sodium ascorbate for 24 h.154 The cytotoxicity under 
these conditions was comparable with that under copper-free conditions.146, 147, 151, 154 This 
latter, the so-called copper-free strain-promoted azide-alkyne cycloaddition (SPAAC) was 
developed by the Bertozzi group for live cell application.128, 132, 152, 155-165 It excludes the 
application of the cytotoxic copper salts, but the rate of the SPAAC is lower than that of the 
CuAAC.152, 155 Even the most reactive strained alkyne biarylazacyclooctynone reacted 
significantly slower with azides than alkynes in the ligand-accelerated CuAAC reaction.128 
Furthermore, the nonspecific conjugation of cyclooctynes to the thiols of Cys containing 
proteins can be significant.152, 155-164, 166-169 The inverse electron-demand Diels-Alder reaction 
between a strained alkene like norbornene or trans-cyclooctyne and a tetrazine is also an 
alternative for bioconjugations.126, 166 The tetrazine dienophile of these cycloadditions is also 
Michael acceptor, therefore the chemoselectivity is limited by the competing Michael addition 
of biological nucleophiles.167-169 Furthermore, the complicated synthesis of tetrazine and 
trans-cyclooctyne reagents inhibits their widespread application in bioconjugations.160, 161, 170 
Since cholesterol can be applied as a protein membrane delivery vector, it suggests 
another application for introducing a bioorthogonal function to the plasma membrane of live 
cells. This way biomolecules containing a complementary function can be directly conjugated 
to the cholesterol moiety pre-incorporated into the outer leaflet of the plasma membrane 
(Figure 9). In this method the amphiphilic cholesterol-azide is delivered to the plasma 
membrane and then a protein equipped with a fluorescent alkyne linker is conjugated via a 
CuAAC reaction. 
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2. Aims of this work 
1. Synthesis of fluorescent cholesterol derivatives for protein membrane delivery and for 
mimicking GPI anchors. 
2. Optimization of the protein conjugation of the water soluble cholesterol anchors. 
3. Investigation of the cell membrane delivery of fluorescent cholesterol anchors and that of 
their protein conjugates. 
4. Anchoring the full length prion protein to the cell membrane with a fluorescent cholesterol 
anchor. 
5. Quantitation of the membrane delivered cholesterol anchor by using a tritium labelled 
analogue. 
6. Application of the cholesterol anchor in cell-surface protein conjugations. 
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3. Experimental  
The purity of all reagents and solvents were analytical or the highest commercially available 
grade. Amino acids and fluorescein derivatives were purchased from Bachem Feinchemicalen 
AG (Bubendorf, Switzerland), coupling reagents (DIC, HOBt, TBTU, HATU) were obtained 
from Calbiochem-Novabiochem AG (Läufelfingen, Switzerland), CLEAR amide resin was 
from Peptides International (Louisville, USA), other chemicals were from Sigma-Aldrich Ltd. 
(Budapest, Hungary). 
Analytical thin layer chromatography (TLC) was performed on 5×10 cm glass plates 
precoated with silica gel 60 F254 (Merck, Darmstadt, Germany), spots were visualized with 
UV light, ninhydrin or phosphomolybdic acid. 
Flash chromatography was carried out on silica gel 60 (Sigma-Aldrich Ltd., Budapest, 
Hungary) using the indicated solvents. 
Analytical HPLC separations and semipreparative HPLC purifications were performed 
with a Merck-Hitachi LaChrom system under the indicated conditions. 
Specific optical rotation was determined with an Optical Activity AA-5 automatic 
polarimeter at 589.4 nm. 
The structure of the compounds was determined by measuring 1D (1H, 13C) and 2D 
(HSQC, HMBC) NMR spectra which were recorded on a Bruker Spectra DRX 500 MHz 
spectrometer. Proton and carbon assignment of the cholesterol moiety was based on literature 
data171. 
Molecular weight of the compounds was determined by ESI-MS analysis on a Finnigan 
TSQ 7000 or on a Bruker reflex III MALDI-TOF spectrometer. 
FT-IR spectra were recorded with a Bio-Rad Digilab Division FTS-65A/896 FT-IR 
spectrometer in the 4000–400 cm-1 interval at 4 cm-1 optical resolution using a diamond ATR 
probe or in KBr pellets. 
Fluorescence excitation and emission spectra were recorded on an Agilent Cary Eclipse 
fluorescence spectrophotometer. 
ECD spectra were recorded on a Jasco (Tokyo, Japan) J815 spectropolarimeter, equipped 
with a Peltier temperature controller, at 25°C and 100 nm/s scan speed using a 1 mm path 
length quartz cuvette. Protein concentration of the samples was in the 2.5 – 6.5 μM range as it 
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was measured by the Bradford method.172 Spectra presented here are accumulations of 10 
scans and the corresponding solvent spectra recorded under the same conditions were 
subtracted. The contribution of each secondary structural element of the proteins was 
determined by deconvolution of the spectra using the CDSSTR method.173 
For in vitro biological studies, SH-SY5Y (ATCC: CRL-2266) human neuroblastoma cells 
were cultured in DMEM (Sigma Ltd., St. Louis, MO, USA) medium containing 10% FCS, L-
glutamine (2 mM), gentamycin (160 μg/mL), 1 mM pyruvate and non-essential amino acids 
(Sigma Ltd., St. Louis, MO, USA). The cells were maintained at 37°C in a humidified 
atmosphere with 5% CO2. 
Cells treated with the fluorescent anchors or protein conjugates were visualized with an 
Olympus IX81 confocal laser scanning microscope and FluoView 500 software. For 
fluorescent membrane staining 20000 cells per well were plated on 8-well Lab-Tek II 
Chambered coverglass. After 48 h incubation at 37°C, cells were treated with the anchors 
dissolved in serum-free medium for 30 min. The concentration of probe 29, anchors 19, 20, 
22, 23 and 25 was 1 μM, and the concentration of 21 and 24 was 10 nM. The mCherry–20 and 
PrP–20, PrP–21 conjugates were applied at 10 μM, while mCherry–4 at 60 μM. Cells treated 
with serum-free medium for 30 min were used as negative control. After treatment and 
incubation, cells were washed with serum-free medium and the nucleus of the cells was 
stained for 5 min using the nuclear dye DRAQ5. 
 
4. Results and discussion 
The major goal of these studies was the synthesis of fluorescent cholesterol derivatives as 
protein delivery vectors to introduce proteins to the plasma membrane of live cells. 
Furthermore, the semisynthesis of homogenous cholesteryl lipoproteins was also intended, 
especially a PrP derivative, to achieve potential lipid raft targeting. Crucial points were to 
retain the native fold of the protein and to attempt fluorescent lipoprotein preparations free of 
both surplus lipids and detergents. 
4.1. Molecular design 
At the design of the synthetic anchors one of the main aspects was the fast and chemoselective 
coupling between the anchor molecule and the protein with its conserved structure. For this 
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purpose the Michael addition was chosen that requires the separate incorporation of a Michael 
acceptor like an α,β-unsaturated carbonyl group and a nucleophilic Michael donor like a thiol 
into the membrane anchor and the protein. In our semisynthetic concept the anchor molecule 
contains the Michael acceptor maleimido or vinylsulfone function in the headgroup, while the 
C-terminal thiol was introduced into the proteins by C-terminal Cys extension. Thiol 
functionalization of peptides and proteins is frequently used for protein bioconjugations, and 
its application is increasing since the native chemical ligation was developed.174 The synthetic 
anchor has to contain a fluorescent reporter as well, which serves for imaging the cell 
membrane anchoring of the attached protein. Finally, the physicochemical properties of the 
anchor molecule are also important, because live cell applications are performed in polar cell 
culture media where the hydrophobicity of the lipid moiety must be compensated to avoid 
precipitation. Accordingly, an additional key function of the molecule is an oligo(ethylene 
glycol) chain, which increases the polarity of the anchor, exposes the headgroup to the 
extracellular space and keeps a distance between the protein and the membrane surface 
similarly to the native GPI anchor. The distance of the protein C-terminal α-carbon atom from 
the glycerol oxygen atom in a GPI corresponds to 29 bonds, while the distance of the protein 
C-terminal α-carbon atom from the cholesterol 3β-oxygen atom corresponds to 30 bonds. 
Thus, the cholesterol anchor can expose the attached protein to the extracellular space with a 
 
Figure 10. Comparison of the GPI anchor with a designed semisynthetic analogue. 
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Scheme 1. Preparation of fluorescent cholesterol anchors. a) HOBt, DIC, THF, RT, 8h, 90%; b) TFA/CH2Cl2 
(1:1), RT, 0.5h, 96%; c) X= BODIPY: carboxypropyl-BODIPY, TBTU, DIEA, CH2Cl2, RT, on., 70% (3), 63% 
(8), X= FL: FITC, DIEA, THF, RT, 8h, 69% (4), 72% (9), X= Cy5: carboxypentyl-Cy5, HATU, DIEA, DMF, 
RT, on., 56% (5), 60% (10); d) TBTU, DIEA, CHCl3/CH2Cl2/DMF 8:2:1, RT, on., 70%; e) TBTU, DIEA, 
CHCl3/CH2Cl2 (4:1), RT, 8h, 90% (n= 3), 85% (n= 8); f) NaAsc, CuSO4.5H2O, CH2Cl2/H2O (1:1), RT, 8h, 87% 
(13), 79% (14), 75% (15); g) X= BODIPY: carboxypropyl-BODIPY, TBTU, DIEA, CH2Cl2, RT, on., 50% (19), 
48% (22), 45% (25); X= FL: FITC, DIEA, DMF, RT, 6h, 74% (20), 68% (23), 64% (26); X= Cy5: 
carboxypentyl-Cy5, HATU, DIEA, DMF, RT, on., 57% (21), 55% (24); h) X= BODIPY: NaAsc, CuSO4.5H2O, 
CH2Cl2/H2O (1:1), RT, 18h, 38% (19), 32% (22), 37% (25), X= FL: NaAsc, CuSO4.5H2O, tBuOH/H2O (1:1), 
RT, on., 57% (20), 51% (23), 52% (26), X= Cy5: NaAsc, CuSO4.5H2O, tBuOH/H2O (1:1), RT, 48h, 42% (21), 
50% (24). 
distance of ca. 20 Å from the surface of the membrane bilayer. The lipid anchor cholesterol is 
attached to the oligo(ethylene glycol) chain, which can target the whole protein–anchor 
conjugate to the cell membrane (Figure 10). The structures of the designed anchors 19 – 26 
are shown on Scheme 1. 
18 
 
4.2. Synthesis of cholesterol anchor 
The cholesterol anchors were synthesized in convergent way from the trifunctional amino acid 
propargylglycin (Pra). Its amino and carboxyl functions were used for coupling the 
fluorescent reporter and the Michael acceptor, and the alkyne function was used for coupling 
to an azido cholesterol derivative by CuAAC. Nα-Boc Pra was coupled to the Michael 
acceptors amino-maleimide 1 or the amino-vinylsulfone 6 (Scheme 1). These two Michael 
acceptors have different pH dependent reactivity with nucleophiles like thiols or amines. After 
the acidolytic removal of the Nα-Boc protecting group of 1 and 6, the ammonium salts of the 
desired compounds 2 and 7 were formed. The fluorescent Pra derivatives 3, 4, 5 and 8, 9, 10 
were prepared from the amines liberated in situ from the ammonium salts of 2 and 7. The 
azido lipids 11 and 12 were prepared from cholesteryl hemisuccinate and the high 
hydrophobicity of the cholesterol residue was compensated with oligo(ethylene glycols) of 
different length. Accordingly, N-acylation of 1-amino-11-azido-3,6,9-trioxaundecane or O-(2-
aminoethyl)-O'-(2-azidoethyl)hepta-ethylene glycol with cholesteryl hemisuccinate was 
achieved in the presence of TBTU and DIEA. The cholesterol anchors 25 and 26 with an 
octaethoxy linker were also prepared, because the increased polarity of the anchor might be 
required for the extracellular exposure of the attached protein. In the final step, the 
functionalized fluorescent Pra derivatives 3, 4, 5 and 8, 9, 10 (Table 1.) were linked to the 
azido-cholesterol derivative 11, furthermore 3 and 4 were coupled to 12 by CuAAC. Beyond 
this strategy, another synthetic route was also investigated. It was found that the introduction 
of the fluorophores is more cost-effective in the last step therefore the amines 16, 17 and 18 
were prepared. The purification of their Nα-Boc protected precursors 13, 14 and 15 was found 
to be more efficient than that of the anchors from the cycloaddition reaction mixture. 
4.3. Optimization of fluorescent cholesterol anchors 
First the BODIPY labelled cholesterol anchors were prepared, because this dye contains only 
a carboxyl group that minimizes the possible side-reactions during the N-acylation of 2 and 7. 
Furthermore, its high brightness facilitates the sensitive detection of the corresponding 
anchors. After the preparation of 3 and 8, azido-cholesterol 11 was captured to these BODIPY 
labelled-linkers that resulted in the cholesterol anchors 19 and 22. But it turned out that both 
the headgroup components 3 and 8, and the BODIPY-labelled anchors 19 and 22 
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Table 1. Spectral properties of the fluorescent linkers. 
Linker Fluorophore ε (cm-1M-1) λex (nm) λem (nm) 
 
3, 4, 5 
 
8, 9, 10 
 
3, 8 x= BODIPY 
80 000 498 510 
 
4, 9 x= fluorescein 
77 000 495 518 
 
5, 10 x= Cy5 
220 000 650 666 
 
were hardly soluble in polar solvent like the serum-free media (DMEM). Significant 
precipitation was observed during the confocal microscopy experiments when cells were 
treated with these compounds (Figure 11). When lower concentration of these anchors was 
applied, there was no detectable membrane staining, while increasing the concentration 
resulted in more precipitate. In order to decrease the hydrophobicity of the BODIPY-labelled 
anchors, the triethoxy linker of 19 was replaced with a more hydrophilic octaethoxy linker. 
The cholesterol azide 12 was conjugated with BODIPY-labelled linker 3 that resulted in the 
anchor 25. During the treatment of SH-SY5Y cells with 25, it was found that this extension of 
the oligoethoxy linker was not sufficient to achieve reasonable solubility in the serum free 
medium, and accordingly the precipitation-free cell membrane staining was not achieved. 
In order to increase the water solubility of the BODIPY-labelled anchors, the β-
cyclodextrin inculsion complex was investigated. β-cyclodextrin is a cyclic oligosaccharide 
with an apolar cavity that has a capacity to form water-soluble inclusion complexes with 
various compounds including cholesterol.175-178 At low β-cyclodextrin concentration, 
cholesterol can be incorporated into the cell membrane within a few minutes,176 because the 
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Figure 11. Association of 10 μM A) 19, B) 22 and C) 25 with SH-SY5Y cells. 
   
Figure 12. Association of 1 μM A) 19–β-cyclodextrin inclusion complex and B) 19 with SH-SY5Y cell 
membranes. C) (─) Emission spectra of 100 μM 19 in PBS without β-cyclodextrin, and (---) emission spectra of 
1 μM 19–β-cyclodextrin inclusion complex in PBS at 25°C; λex= 488 nm. 
exchange rate of cholesterol between β-cyclodextrin and membranes is high. At μM 
concentrations, β-cyclodextrin does not extract cholesterol from the cell membrane, it requires 
β-cyclodextrin in mM concentration range.179 Furthermore, β- cyclodextrin does not 
accelerate the extraction of phospholipids from the cell membrane when the concentration of 
β-cyclodextrin is below 20 mM.180 In the form of this inclusion complex, BODIPY-labelled 
anchors 19 and 22 exhibited intense membrane staining at 1 μM concentration without 
significant precipitation. In contrast, the presence of 1 μM 19 without β-cyclodextrin in the 
medium did not result in membrane staining (Figure 12). The fluorescent spectra of 19 and 
19–β-cyclodextrin inclusion complex represent the differences in the solubility of these 
species. According to this finding, it was concluded that these synthetic anchors could be 
applicable for protein conjugation and subsequent imaging. 
A  CB 
A  B  C
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Figure 13. Association of 1 µM A) 20, B) 23 and C) 26 with SH-SY5Y cells. 
In order to optimize the headgroup of the anchor, the incorporation of polar fluorescent 
reporters that could exclude the application of β-cyclodextrin was investigated. For this  
approach fluorescein isothiocyanate was used. Its phenolic hydroxyl group gives a possibility 
for salt formation with amines. Thus, the fluorescein-labelled cholesterol anchors 20, 23 and 
26 were synthesized and the corresponding triethylammonium and 
diisopropylethylammonium salts were prepared. It was found, that the solubility of these 
ammonium salts (20, 23 and 26) was higher in serum free medium than that of the BODIPY 
analogues 19, 22, 25. When SH-SY5Y cells were treated with these fluorescent cholesterol 
derivatives, no fluorescent precipitates were observed that indicated the appropriate 
physicochemical properties of these anchors (Figure 13). Furthermore, no significant 
difference was detected between the cell membrane association of 19 and 25 suggesting that 
incorporation of a polar fluorophore into the headgroup produces more significant effect on 
the water solubility than the slight extension of the oligoethoxy linker. When these 
amphiphilic compounds are dissolved in aqueous buffers, they form highly stable micellar 
associates with an approximate critical micellar concentration of 10 – 100 nM.122 The 
hydrophobic cholesterol moieties form the core of the micelle and the hydrophilic headgroups 
are situated at the hydrated surface of the micelle. Importantly, in these micelles the protein 
conjugation Michael acceptor group is accessible by nucleophilic groups during protein 
conjugation. 
The application of fluorescein was found to be advantageous to obtain soluble cholesterol 
anchors, but the pH-dependent fluorescence181 and the low photostability of fluorescein 
inspired us to substitute fluorescein with a sulfonated pentacyanine (Cy5) dye. This Cy5 
derivative is highly water soluble and the fluorescence properties (high brightness, 
photostability) are advantageous for sensitive detection of low amount of anchors and also for  
A  B  C
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Figure 14. Association of 10 nM A) 21 and B) 24 with SH-SY5Y cell membranes. 
 
Anchor Fluorescence spectrum Membrane association 
  50 μM 19-β-cyclodextrin complex in PBS 
 
 SH-SY5Y cells + 1 μM 19  
  50 μM 20 in PBS   SH-SY5Y cells + 1 μM 20 
  0.5 μM 21 in PBS 
 
SH-SY5Y cells + 0.01 μM 21 
Figure 15. Comparison of the synthetic anchors 19-21. 
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multiple imaging.83 The maleimido and the vinylsulfone derivatives of Cy5-labelled anchor 
21 and 24 were prepared, but the analogue with an octaethoxy linker was not necessary. In 
fluorescence microscopic studies intensive membrane staining was observed when SH-SY5Y 
cells were incubated at 10 nM with 21 or 24 (Figure 14). For comparison, similar membrane 
fluorescence required the presence of 1 μM fluorescein-labelled analogues in the cell culture 
medium.  
The fluorescence spectra of fluorescent anchors 19-21 were recorded, and the 
concentration of BODIPY-labelled 19 in cyclodextrine inclusion complex and the fluorescein-
labelled 20 was 50 μM, while that of the Cy5-labelled 21 was 0.5 μM (Figure 15). The equal 
fluorescence intensity on the spectra indicated the differences in the effective concentration 
for cell treatment. 
4.4. Investigation of the hydrolytic stability of the cholesterol anchor 
Before protein conjugation to the cholesterol anchors and cell membrane delivery of the 
attached protein, the hydrolytic stability of the cholesteryl ester that is the connection between 
the headgroup and the cholesterol moiety was investigated. For that purpose, the fluorescein-
labelled model compound 29 was synthesized and subjected to preliminary studies. In order to 
avoid side-reactions with nucleophiles of biomolecules, this compound does not contain 
Michael acceptor. The cholesterol probe 29 was prepared from cholesteryl hemisuccinate. It 
was activated with TBTU in the presence of DIEA, and used for the N-acylation of the mono-
trityl protected 1,13-diamino-4,7,10-trioxa-tridecane (Scheme 2). The trityl group was chosen 
 
Scheme 2. Synthesis of the fluorescent cholesterol probe: a) TBTU, DIEA, CHCl3/CH2Cl2 (4:1), RT, 8h, 95%; 
b) TFA, TIS, CH2Cl2, RT, 5×10 min, 94%; c) FITC, DIEA, DMF, RT, 6h, 47%. 
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Figure 16. (A) Hydrolytic stability of the fluorescent cholesteryl probe 29. The peak area of 29 in the incubated 
sample is indicated as a fraction of the peak area of 29 in the starting solution. (B) SH-SY5Y cells were treated 
with 1 µM 29 for 30 min, and nuclear staining was carried out with DRAQ5 for 5 min. The fluorescein is green, 
and the nuclei are blue in the image. 
for protecting the terminal amine, because it is cleaved by mild acids under a condition where 
the cholesteryl ester is stable. The acidolytic removal of the trityl group of 27 was performed 
in the presence of triethylsilane that prevented the realkylation of the amine 28 during the 
deprotection. Finally, the addition of the amine 28 to fluorescein isothiocyanate resulted in the 
cholesterol probe 29. The hydrolytic stability of the cholesteryl ester in 29 was explored by 
incubating the probe in PBS at ambient temperature and HPLC analyses were performed at 
regular time points. It was found that the HPLC peak area of the probe remained constant over 
a period of 24 h (Figure 16), indicating that the cholesteryl ester was not hydrolyzed. In a 
subsequent experiment SH-SY5Y cells were treated with 1 μM of 29, and an intensive 
membrane staining was observed (Figure 16). 
These experiments suggested that the cholesteryl ester of the anchors was stable under 
physiological conditions, and the hydrophilic headgroup did not prohibit the fast membrane 
insertion of the cholesterol amphiphile. 
4.5. Optimization of the Michael addition of the cholesterol anchors  
The Michael addition of the maleimido and the vinylsulfone derivatives of fluorescein-
labelled anchors 20 and 23 was optimized using a model peptide H-Cys-Lys(biotin)-Asp-Glu-
Gly-Asp-Gly-NH2 containing an N-terminal Cys residue. The peptide was added to the 
solutions of 20 or 23 (0.6 mM) at different pH, and after 10 min incubation time the samples  
B A 
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Figure 17. pH dependence of the Michael addition of 20 and 23. 1 equ (--) or 0.5 equ (―) of H-Cys-
Lys(biotin)-Asp-Glu-Gly-Asp-Gly-NH2 was added to the solution of 0.6 mM 20 (A) or 23 (B) in 20 mM MES, 
10 mM TCEP pH5.5 – 6.5 or in 20 mM Tris, 10 mM TCEP pH7.0 – 9.5. After 10 min incubation time HFIP was 
added to the solution and it was analysed by HPLC. 
of the mixtures were analysed by HPLC. The conversion of the peptide was calculated from 
the peak areas of the unreacted peptide. In case of the Michael acceptor and donor were 
present in equimolar ratio, the maleimide was found to be more reactive than the vinylsulfone 
between pH 5.5 and 7.5. When the cholesterol anchors 20 and 23 were applied in two-fold 
molar excess over the peptide, quantitative anchor – peptide conjugation was observed in the 
investigated pH range with the maleimido anchor 20, and above pH 8 with vinylsulfone 
anchor 23 (Figure 17). 
Maleimides are more reactive than vinylsulfones with thiols, because maleimides are more 
electrophilic, but under basic conditions, above pH 7.5, maleimides can react with amines also 
which decreases the chemoselectivity of the Michael addition-based bioconjugation.83 In 
contrast, the weaker electrophile vinylsulfone is less reactive toward nucleophiles, but its thiol 
addition is significantly faster than the amine addition that results in higher chemoselectivity 
between pH 7.5 and 9.0.182, 183 Furthermore, maleimides can hydrolyze under mild basic 
conditions to maleic acid that is disadvantageous when a longer reaction time is required for 
capturing of the cholesterol anchor to a protein with a sterically hindered C-terminus. When a 
prolonged reaction time is necessary, the vinylsulfone containing anchor is to be the choice 
because it was found to be stable for days at pH 9. 
A B 
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4.6. Semisynthesis of cholesteryl mCherry 
The red fluorescent protein mCherry lacking any native Cys residues was chosen to optimize 
the protein – cholesteryl anchor conjugation, and to demonstrate that the designed fluorescent 
cholesterol derivatives can anchor proteins to the cell membrane. The protein has a sensitive 
fluorophore within a β-barrel structure. If it is denatured, the red fluorescence of the protein is 
lost, and thus, the existence of the protein red fluorescence is an indicator of preserving the 
native protein structure after cholesterol anchor conjugation. If a green fluorophore containing 
anchor is used for the mCherry conjugation, then a dual fluorescent cholesteryl lipoprotein is 
obtained. After introducing this conjugate to the cell membrane, both the cholesterol anchor 
and the protein can be directly visualized by fluorescence microscopy. Further advantage of 
this two-color fluorescent lipoprotein conjugate is that the equimolarity of the protein and the 
anchor can easily be assessed by SDS-PAGE and by measuring the intensity of the 
fluorescence emissions. 
The C-terminal Cys extension of mCherry resulted in a protein that possessed a single 
Michael donor thiol group assuring the chemoselective addition of anchors to the protein C-
terminus. mCherry-Cys was overexpressed in E. coli with a His6 tag preceding the C-terminal 
Cys residue, and was purified from the soluble fraction of the E. coli lysate by Ni-affinity 
chromatography. The conjugation of the BODIPY-labelled cholesterol anchor 19 to the Cys 
extended mCherry was performed in 20 mM Tris, 10 mM TCEP at pH 7.5. Under these 
conditions the β-barrel structure of the protein remains intact.  
The hydrophobic anchor 19 was applied in β-cyclodextrin complex and the maleimide was 
presumed to support a fast reaction under these conditions. But the Michael addition went 
slowly between 19 and mCherry-Cys and the formation of precipitate was also observed. The 
SDS-PAGE and MALDI analyses of the precipitate revealed the presence of the unreacted 
cholesterol anchor and the mCherry–19 conjugate. 
In order to avoid the precipitation of the cholesterol anchor – protein conjugate, the 
mCherry–fluorescein-labelled anchor 20 conjugate was prepared under similar conditions as 
described above. It was found that the total conversion of mCherry-Cys required 25-fold 
molar excess of 20 in 1h (Figure 18). This ratio suggests that the micelles of 20 is composed 
of ca. 25 cholesterol amphiphils, and also that a micelle reacts with a single protein molecule 
because of the sterical hindrance of protein. On preparative scale a protein to anchor ratio of  
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Figure 18. A) Conjugation of fluorescein-labelled cholesterol anchor 20 with mCherry-Cys. The schematic 
green heads represent the green fluorophore of the cholesterol anchor 20. B) The conversion of mCherry-Cys 
after 1h in the presence of different anchor excess. 
1:10 was applied, and the total amount of 20 was added in 10 portions over 5h. After the 
Michael addition, the mixed micelles of the cholesteryl mCherry conjugate and the anchor 20 
amphiphils were separated from both the unreacted protein and from the anchor 20 micelles 
by gel chromatography (Figure 19). According to the elution time, the micellar associates of 
this cholesteryl mCherry preparation exhibited a virtual molecular weight significantly higher 
than that of the mCherry. The gel chromatographic fraction containing the mCherry–anchor 
20 conjugate was subjected to SDS-PAGE, and an intensive fluorescence was detected in the 
dye front indicating the presence of mixed micelles (Figure 20). These mixed micellar 
associates keep the cholesteryl lipoprotein dissolved in an aqueous medium. However, it is 
essential to remove the surplus fluorescent cholesterol, otherwise the plasma membrane or the 
cholesterol homeostasis184 could be perturbed during live cell imaging applications. 
Furthermore, if the mixed micelles of the conjugate are used for the introduction of the 
lipoprotein into the cell membrane, the unambiguous imaging of the membrane anchored 
protein will be impossible via the fluorescence of the cholesterol anchor. 
In order to prepare biologically relevant cholesteryl lipoproteins different methods 
were investigated for the separation of the cholesteryl lipoprotein from the surplus fluorescent 
cholesterol anchor with an emphasis on the retention of the protein structure. If it is achieved, 
the fluorescence of the cholesterol anchor can be assigned to the attached protein, and thus, 
the protein can be unambiguously visualized after cell membrane delivery of the 
semisynthetic construct. It is important e.g. when the cellular traffic of the exogenously 
introduced cholesteryl lipoprotein is to be imaged. 
A B 
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Figure 19. Purification of the mixed micelles of the mCherry–anchor 20 conjugate (fraction 1) followed by the 
separation of the β-cyclodextrin inclusion complex of mCherry–20 (fraction 2) and that of the 20 excess (fraction 
3) on Superdex 75 with 50 mM Na2HPO4, 150 mM NaCl, pH7.0, flow rate 0.6 mL/min, λ= 216 nm. 
Dialysis is commonly used to remove small molecules or lipid excess from protein samples, 
however, the stability of the mixed micelles of fluorescein-labelled anchor 20 and cholesteryl 
mCherry limits the performance of this technique. Extraction of the surplus cholesterol anchor 
with apolar solvents is another option, but the application of chloroform denatured the protein. 
Refolding of such a denatured cholesteryl lipoprotein was not feasible, because the cholesterol 
residue permanently participates in hydrophobic interactions, and thus, restricts the protein 
folding. On the other hand, the application of detergents results in mixed detergent micelles of 
the cholesteryl lipoprotein which are free of surplus fluorescent cholesterol anchors. The 
introduction of the cholesteryl lipoprotein into the cell membrane is possible via such 
detergent micelles, but the detergent molecules have a membrane perturbing effect that is to 
be avoided in biological applications. When the mixed micelles of mCherry–anchor 20 were 
purified by reversed phase HPLC, the mixed micelles were disrupted at an acetonitrile 
concentration of 50% and the cholesteryl mCherry was eluted as a pure semisynthetic product. 
However, the resulting lipoprotein lost the red fluorescent properties indicating the 
distortion of the β-barrel structure of mCherry. Afterwards, the refolding of this denatured 
cholesteryl mCherry failed similarly to that of the chloroform extracted cholesteryl mCherry. 
The application of an anchor capture resin was also intended for the separation of the 
lipoprotein and the anchor excess by filtering off the resin bound anchor. A cysteinyl CLEAR-
amide resin was prepared for that purpose, because it has beneficial water swelling properties. 
The heterogeneous Michael addition, however, was found to be very slow, and the mixed 
micelles remained intact. All efforts that were made for the separation of the cholesteryl 
lipoprotein from any interacting partners of the hydrophobic cholesterol residue failed. 
2 
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Figure 20. (A) Preparation of the lipid excess-free cholesteryl mCherry. The schematic green heads represent 
the green fluorophore of the cholesterol anchor 20, β-cyclodextrin is symbolized with a blue truncated cone, 
SEP.1. and SEP.2. indicate gel chromatographic separations. (B) Coomassie-stained (left) and fluorescence 
detected (right) 15% SDS-PAGE gel: lane 1, molecular weight marker; lane 2, mCherry (under denaturing 
conditions, the acylimine group of the mCherry fluorophore matured from the Met71-Tyr-Gly73 sequence is 
hydrolyzed185, 186 that results in the appearance of additional bands with a Mw of 7.8 and 19.8 kDa); lane 3, mixed 
micelles of cholesteryl mCherry (the cholesteryl derivatives of the full length mCherry and that of the C-terminal 
mCherry fragment, and surplus 20 are fluorescent); lane 4, β-cyclodextrin inclusion complex of cholesteryl 
mCherry (in order to emphasize the lack of surplus anchor 20, a larger amount of lipoprotein was introduced than 
in lane 3); lane 5, cholesterol anchor 20. 
Therefore, another approach was tried, where the cholesterol moiety of the protein–anchor 
conjugate was sequestered by a reversible complexation with β-cyclodextrin, which was 
suitable for increasing the water solubility of 19. When the mixed micelles composed of the 
cholesteryl mCherry and anchor 20 were incubated with 10 eq β-cyclodextrin, the micellar 
associates were disrupted without denaturing the protein. The hydrophobic cavity of the β-
cyclodextrin binds the cholesterol moiety of the conjugate and that of the surplus anchor 
molecules forming host-guest complexes. The molecular weight of the inclusion complex of 
the protein–anchor 20 conjugate is significantly higher than that of the cholesterol anchor, and 
thus, their separation was achieved by size-exclusion chromatography. The purified inclusion 
complex of the lipoprotein was subjected to SDS-PAGE, and the fluorescence detection 
revealed that the mCherry–anchor 20 preparation was free of surplus fluorescent anchor 
(Figure 20). 
 
4.7. Characterization of cholesteryl mCherry 
The fluorescence spectra of the pure mCherry–20 lipoprotein exhibited the characteristics of 
both fluorophores with shoulders on the emission spectrum of fluorescein and on the  
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Figure 21. (A) Excitation (─ λem= 518 nm; ─ λem= 610 nm) and emission (--- λex= 488 nm; --- λex= 543 nm 
and 587 nm) spectra of mCherry–anchor 20 (20 μM in H2O) at 25°C. (B) ECD spectra of mCherry–Cys (red), 
mixed micelles of cholesteryl mCherry (blue) and the β-cyclodextrin inclusion complex of cholesteryl mCherry 
(green). 
excitation spectrum of mCherry (Figure 21). The emission spectrum of the red fluorophore 
was also recorded at an excitation wavelength of 543 nm, because it was applied during the 
confocal laser scanning microscopic experiments. The red fluorescence of the β-cyclodextrin 
inclusion complex of cholesteryl mCherry was indicative about the retention of the native 
protein fold, but it was further evidenced by ECD spectroscopy. ECD spectra of the Cys 
extended mCherry and that of the mCherry–anchor 20 conjugate indicated that the attachment 
of the cholesterol anchor does not cause significant change in the protein structure and that the 
-barrel fold of mCherry is intact both in the mixed micellar form and in the β-cyclodextrin 
inclusion complex. The fractions of the secondary structural elements of the lipoprotein were 
calculated by deconvoluting the ECD spectra (Table 2), and they were compared with that of  
Table 2. Fractions of secondary structure elements in mCherry 
 
aResults obtained from PDB 2H5Q by DSSP algorithm. bResults obtained from PDB 2H5Q by STRIDE 
algorithm. cResults obtained from experimental ECD spectra by deconvolution. 
Protein Helix -Sheet Turns Random 
mCherrya 0.06 0.57 0.16 0.14 
mCherryb 0.05 0.58 0.27 0.11 
Cys extended mCherryc 0.09 0.40 0.24 0.27 
mCherry–anchor 20 conjugatec 0.05 0.43 0.24 0.28 
mCherry–anchor 20 conjugate with -CDc 0.07 0.41 0.25 0.26 
B 
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the parent mCherry. The distribution of the secondary structural elements was also calculated 
from the X-ray diffraction structure of mCherry (PDB 2H5Q) for comparison. The crystal 
structure was analyzed with both the DSSP187 and STRIDE188 secondary structure recognition 
algorithms, which yielded very similar results. In the solution structures of mCherry–Cys and 
mCherry–20, slightly higher fractions of random structures and lower fractions of β-strands 
were found. 
4.8. Cell membrane association of cholesteryl mCherry 
It was evidenced that our approach offers an effective way to prepare fluorescent cholesteryl 
lipoproteins without denaturing the protein structure. The resulting semisynthetic lipoproteins 
do not contain surplus lipids that were achieved without the use of detergents. As a 
consequence, the fluorescence signal of the anchor molecule can be unambiguously assigned 
to the attached protein, and the membrane perturbation by external lipid excess or detergents 
can be excluded in live cell imaging applications. Confocal laser scanning microscopy images 
of SH-SY5Y cells incubated with the -cyclodextrin inclusion complex of the semisynthetic 
mCherry–anchor 20 conjugate showed green and red fluorescence on the cell membrane 
(Figure 22). It suggests that the protein was successfully anchored to the cell membrane after 
exogenous addition, and also that the protein structure was not affected by the membrane 
association. Red fluorescence was not observed when cells were treated with the Cys 
extended mCherry, confirming that the cholesteryl lipoprotein firmly associated to the cell 
membrane via the cholesteryl anchor. It is important to note, that the fluorescent reporter is 
situated extracellularly, as it was clarified by MD simulations on the anchor 20, and only the 
cholesterol residue is immersed into the outer leaflet of the membrane bilayer. This spatial 
arrangement of the conjugate helps to maintain lipid-lipid interactions specific for cholesterol, 
and proposes lateral diffusion properties similar to that of the cholesterol. These membrane 
biophysical properties would be altered if the sterane skeleton was modified with a fluorescent 
molecule.189 The colocalization of the fluorophores also evidenced that the cholesteryl ester 
and consequently the whole conjugate was stable under the circumstances of the live cell 
imaging. It is also visible on the differential interference contrast picture that the conjugate is 
not toxic for the SH-SY5Y cells. This finding is in agreement with the results of the MTT 
assays, where the mCherry–20 conjugate was found to be non-toxic at the concentration of 10 
μM. The membrane association of the conjugate results in the liberation of β-cyclodextrin  
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Figure 22. Confocal laser scanning and differential interference contrast (right bottom) microscopy of SH-
SY5Y cells after 30 min incubation (A) with 1 μM fluorescein-labelled cholesterol anchor 20, and (B) with β-
cyclodextrin inclusion complex of 1 μM cholesteryl mCherry at 37°C. On the images fluorescein is green, 
mCherry is red and nuclei are blue. On the overlayed image (A and B, left bottom) yellow represents the 
colocalization of the fluorescein and mCherry signals. 
from the inclusion complex. However, the presence of 10 – 20 μM β-cyclodextrin in the cell 
culture medium has no effect on the normal cellular cholesterol level, because the cholesterol 
extraction from the cell membrane requires higher β-cyclodextrin concentration in the mM 
range.179 
4.9. Conjugation of the full length prion protein with cholesterol anchors 
Due to easier availability of the mouse PrP (mPrP), human PrP was replaced by the murine 
homologue in experiments described in this thesis. The mouse PRNP gene encodes a 
precursor protein with 254 amino acids which has a sequence homology of > 90% to the 
human PrP. The maturation is analogous to the human PrP described in section 1.3 that yields 
a GPI-anchored PrPC of 208 amino acids, which is transferred to the exterior leaflet of the cell 
membrane. 
In contrast to the mCherry, the Cys extended full length mPrP has three Cys residues, but 
the chemoselective addition of an anchor molecule to the C-terminal thiol can be achieved. 
The native Cys178 and Cys213 forms an intramolecular disulfide bond that is buried between α-
helices of the folded mPrP excluding them from both thiol-disulfide exchange reactions and 
subsequent Michael addition. The native disulfide was formed during the folding on Ni-NTA 
agarose in the presence of the redox system of reduced and oxidized glutathione, and only the 
properly folded S231C mPrP[23-231] protein was eluted from the affinity matrix. Then the  
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Figure 23. (A) RP-HPLC purification of the S231C mPrP(23-231) – 20. S231C mPrP(23-231) eluted in 
fraction 1, S231C mPrP(23-231) – 20 eluted in fraction 2 and 20 eluted in fraction 3. (B) Re-purification of 
fraction 2, under the same conditions as in (A), fraction 4 was collected. 
Michael addition of the Cys-extended mPrP to fluorescein-labelled anchor 20 was achieved in 
20 mM Tris, 10 mM TCEP, pH 7.0. Anchor 20 was added to the protein in 10-fold molar 
excess in ten portions over 5 h. The mPrP–anchor 20 conjugate precipitated together with 
denatured mPrP, and the precipitate was dissolved in formic acid and introduced to RP-HPLC 
for purification (Figure 23). The pure conjugate was dissolved in 20 mM NaOAc, pH 5.5 
containing 0.5 mM β-cyclodextrin for the formation of the inclusion complex. The purified 
inclusion complex of the mPrP-anchor 20 conjugate was subject to SDS-PAGE, and the 
fluorescence detection revealed that the mPrP–anchor 20 preparation was free of surplus 
fluorescent anchor (Figure 24). CD spectroscopy revealed that the higher order structure of 
the conjugate was slightly different from the purified S231C mPrP[23-231]. While the 
spectrum of the folded S231C mPrP(23-231) exhibited distinct α-helical character with  
      
Figure 24. A) Preparation of mPrP–20. B) SDS-PAGE (15%): lane 1, molecular weight marker; lane 2, S231C 
mPrP[23-231]; lane 3, inclusion complex of mPrP–anchor 20 conjugate; lane 4, anchor 20. 
4 
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Figure 25. ECD spectra of folded S231C mPrP(23-231) (red) and S231C mPrP(23-231)–anchor 20 conjugate 
in the presence of -cyclodextrin (blue). Fractions of secondary structure elements identified by the 
deconvolution of the ECD spectra. 
minima at 208 and 222 nm, and a maximum around 195 nm, the spectrum obtained for the full 
length mPrP–anchor 20 conjugate is more of a β-sheet character with a wide minimum around 
215 nm (Figure 25). However, spectral deconvolution indicates 4% higher -sheet content for 
the mPrP cholesterol derivative. This slight structural difference may be caused by the 
preparation conditions (Ni affinity chromatography vs RP-HPLC) and not necessarily by the 
covalent lipidation. The relatively large difference between the ECD spectra of the parent and 
the conjugated proteins may be explained by the fact that helical structures provide more 
intense ECD signals than β- strands, therefore a minor change in helical contribution may 
have such dramatic effects. The fluorescent lipo-PrP preparation was immediately used to 
treat SH-SY5Y human neuroblastoma cells, in 1 μM and 3 μM concentration and the 
membrane association of the green fluorescent cholesteryl mPrP derivative was observed 
(Figure 26). Because PrP is a highly aggregation prone protein, the Cy5-labelled cholesterol  
   
Figure 26. Confocal laser scanning microscopy of SH-SY5Y cells after 30 min incubation with A) 1 μM and 
B) 3 μM S231C mPrP(23-231)–anchor 20, C) 10 nM S231C mPrP(23-231)–anchor 21. 
 Helix -Sheet Turns Random 
S231C mPrP(23-231) 0.13 0.33 0.22 0.32 
S231C mPrP(23-231)–anchor 
20 conjugate with -CD 0.08 0.37 0.23 0.30 
A B C
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anchor 21 was also conjugated to the full length mPrP. Its brighter fluorescent headgroup 
makes the application of this cholesteryl mPrP conjugate possible at lower concentrations that 
decreased the possibility of the protein aggregation. 
4.10. Quantitation of the cell membrane delivery of cholesterol anchors 
In order to determine the concentration of the cell membrane introduced cholesterol anchor , a 
tritium-labelled cholesterol anchor analogue containing a radioactive reporter in the 
extracellularly exposed headgroup was designed.190 The quantitation of the membrane 
incorporated protein anchor requires the measurement of the radioactivity of cell membrane 
preparations therefore the position of the radioactive label is crucial. Although [1,2-
3H]cholesterol complexed with β-cyclodextrin was used for the fast enrichment of cell 
membranes with labelled cholesterol175 and it was also used in studying the cyclodextrin-
mediated cholesterol transfer between different lipid layers,191 it is not an optimal choice for 
our purpose. If the headgroup of the cholesterol anchor is partially removed via the enzymatic 
hydrolysis of the cholesteryl ester, then the cholesterol moiety will remain in the cell  
 
Scheme 3. Preparation of the H-3 labelled cholesterol anchor: a) NaAsc, CuSO4.5H2O, DMF–CH2Cl2–H2O 
(1:4:4), RT, 8h; b) TFA–CH2Cl2 (1:1), RT, 30 min; c) 2 eq DIEA, MeOH, RT, 3h; d) HATU, DIEA, THF, RT, 
16h; e) HOBt, DIC, DMF, RT, 16h. 
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membrane. Accordingly, the process cannot be detected in the case of a cholesterol-labelled 
anchor, because the membrane radioactivity is not affected by the presence or lack of the 
headgroup. In contrast, if the tritium label is in the headgroup of the anchor molecule, the 
esterase activity will result in decreased radioactivity of the membrane preparation, and thus, 
the enzymatic release of the headgroup can be detected in the cell culture medium. 
In order to introduce the radioactive label into the cholesterol anchor headgroup, a 
convergent synthetic strategy was applied (Scheme 3). The tritium label was incorporated into 
a small molecule that was coupled to an anchor fragment bearing both the cholesterol residue 
and the bulk of the headgroup. The advantage of this approach is that tritium incorporation 
either into the cholesterol moiety or into other parts of the headgroup is excluded.  
The cholesterol amphiphile 32 was an appropriate intermediate, because it contains an 
orthogonal function for the protein conjugation, and the carboxylic acid function of the 
headgroup is available for the introduction of a radiolabelled or a fluorescent tag. The 
intermediate 32 was prepared from Nα-tBoc-protected Pra and 11 via a dipolar cycloaddition 
in the presence of CuSO4 and sodium ascorbate. The Nα-tBoc-protecting group was removed 
by TFA in DCM and the amine 31 was liberated in situ with DIEA during the next step. Then 
31 was used for the preparation of two constitutionally related, tritium or fluorescein-labelled 
anchors (35 or 33). 
First the thiol reactive maleimide group was coupled to the amine 31, because this way the 
co-existence of a Michael acceptor and a primary amine in an intermediate compound is 
excluded that otherwise could lead to self-addition under the basic conditions of the 
introduction of the labelling tag. It was found that the amino function of 31 reacts faster with 
an N-hydroxysuccinimide ester than with a maleimide, and accordingly the N-acylation of 31 
with 3-maleimidopropionic acid N-hydroxysuccinimide ester in DMF resulted in 32. This 
maleimide serves as a possible protein conjugation function for biological applications. In 
order to avoid the addition of nucleophiles to the maleimide of 32 an aniline and an alkyl-
hydrazine – both are less basic than primary amines – were used to introduce the fluorescein 
and the tritium label, respectively. 
In a preliminary study it turned out, that the aniline moiety of 5-aminofluorescein did not 
react with the Michael acceptor of (N-(2-maleimidoethyl)-2-aminopent-4-ynamide) under the  
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coupling conditions planned to apply for the preparation of fluorescein-labelled ancohr 33. 
Therefore the fluorescent anchor 33 was obtained by coupling of the carboxyl group of 32 
with 5-aminofluorescein in the presence of the coupling agent HATU. The NMR structure 
investigation revealed that 5- aminofluorescein was conjugated to the carboxylic function of 
32. 
The tritium label was introduced via an aliphatic compound instead of aniline to increase 
the radiolytic stability of the labelled anchor molecule. N-Aminopiperidine was chosen for 
that purpose, because it is less basic than cyclohexylamine, and after N-acylation it results in 
stable hydrazides. Coupling of tritium labelled N-aminopiperidine to the carboxylic acid 
function of 32 results in an anchor molecule possessing a headgroup homologous to that of 
33, and this way the nonspecific tritium incorporation into the cholesterol moiety or into the  
maleimido headgroup is not feasible. Before preparing the tritium-labelled anchor by N-
acylation of [3H]N-aminopiperidine with 32, the unlabelled isotopologue 34 was prepared in 
order to optimize the reaction conditions and carry out NMR measurements. 
Before the preparation of the tritium-labelled N-aminopiperidine, 4-bromopiperidine was 
considered as a precursor in a deuterium labelling experiment (Scheme 4). The 4-
bromopiperidine base was liberated from the hydrobromide salt and it was reduced with 
deuterium gas in the presence of Pd/C (10% Pd) catalyst. The resulting [2H]piperidine 
hydrochloride (36) was analyzed by TLC and ESI-MS. The separation of 4-bromopiperidine 
and piperidine was achieved on silica gel 60 F254 glass plates in n- BuOH−AcOH−H2O 2:1:1, 
as their Rf values were found to be 0.48 and 0.38, respectively. The TLC analysis of the crude 
[2H]piperidine hydrochloride revealed that the conversion of 4-bromopiperidine was 
complete. Furthermore, the deuterium incorporation level was estimated by an ESI-MS 
analysis. It was found that 0.9 deuterium atoms/piperidine molecules were incorporated on  
 
Scheme 4. Preparation of [3H]N-aminopiperidine: a) Pd/C (10% Pd), 2H2(g) (36) or 3H2(g) (37), EtOAc, RT, 3h; 
b) KNO2, 1 M HCl, 0 ºC, 2h; c) LiAlH4, THF, Ar atm., 60 ºC, 3.5h. 
38 
 
 
Species m/z intensitya 
intensityb 
(%) 
M(d0) + H]+ 86 1.63 × 105 (88.59%) 88.59 
M(d1) + H]+ 87 1.84 × 105 (100%) 94.60 
M(d2) + H]+ 88 9.80 × 104 (53.26%) 47.49 
M(d3) + H]+ 89 1.70 × 104 (9.24%) 6.34 
 
Figure 27. ESI mass spectrum of [2H]piperidine and the abundance of the isotopologues. a measured intensity, 
b relative intensity corrected with the natural abundance of 2H and 13C. 
average, but isotopologous species containing two or three deuterium atoms were also 
identified (Figure 27). These results suggested that this precursor is satisfactory for achieving 
an approximate molar activity of 1 TBq/mmol. 
In the next step [3H]N-aminopiperidine was prepared from 4-bromopiperidine (Scheme 4). 
Reduction of the brominated piperidine with tritium gas in the presence of Pd/C (10% Pd) 
catalyst resulted in tritium-labelled piperidine. It was nitrosated and the resulting [3H]N- 
nitrosopiperidine was reduced with LiAlH4, and 37 was isolated as a hydrochloride salt. The 
carboxylic acid 32 was activated with HOBt in the presence of DIC, and the resulting active 
ester was used in situ for the N-acylation of 37 to give the tritium-labelled anchor 35. HPLC 
analysis revealed that a significant amount of tritium-labelled N-aminopiperidine was coupled 
to 32. The purification of the crude cholesterol derivative was achieved by RP-HPLC 
resulting in 17.4 MBq of pure 35 with an isolated radiochemical yield of 17%. The sterical 
hindrance of the carboxylic acid function of 32 and the more diluted reaction mixture as 
compared to that of 33 and 34 resulted in the low yield of 35. Quantitative analysis of the 
concentration and radioactivity of the labelled anchor 35 was performed by RP-HPLC via UV 
and radioactivity detection using a calibration curve made by 34. The specific activity of the 
tritiated cholesterol anchor 35 was found to be 1.37 TBq/mmol that is higher than the 
theoretical value. Beyond tritium substitution of Br in 4-bromopiperidine, catalytic 1H/3H 
exchange reactions also took place presumably at the positions 2 and 6 of the piperidine ring. 
When 2-3 h of reaction time is applied for catalytic dehalotritiation, the catalytic exchange 
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becomes significant and increases the specific activity. The ESI-MS analysis of the 
deuterium-labelled piperidine also indicated catalytic exchange reactions. It is important to 
note that the convergent synthetic strategy ensures that all the tritium atoms are localized in 
the piperidine ring of the headgroup, because after the tritium gas reduction of 4-
bromopiperidine further transformations do not affect the tritium distribution. 
The control compound 33 was used to assess the membrane association properties of the 
tritium-labelled cholesterol anchor. The solubility of 33 was investigated in an aqueous 
medium before the imaging application. It was important to mimic the protein anchoring 
conditions, where the cholesterol anchor exists in β-cyclodextrin inclusion complex. 
Accordingly, 33 was not transformed into the DIEA salt, and it was found that the amphiphile 
33 partially dissolved in a serum free medium as micellar associates and the remaining portion 
formed precipitates. The resulting heterogeneous mixture was incubated with 10 eq β-
cyclodextrin and this way 0.5 mM aqueous solution of 33 was prepared. Then SH-SY5Y cells 
were treated with 1 μM of the inclusion complex of 33 for 30 min. After delivering to live 
SH-SY5Y cells, an intensive membrane staining was observed, i.e. 33 incorporated into the 
cell membrane similarly to fluorescein-labelled anchors 20, 23 or 26 (Figure 28). It indicates 
that a slight modification in the α-amino acid function of the headgroup is tolerated with the 
retention of the membrane association properties. 
The tritium-labelled anchor 35 could also be solubilized in cell culture medium with this  
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Figure 28. A) Confocal laser scanning (left) and differential interference contrast (right) microscopy of SH-
SY5Y cells after 30 min incubation with 1 μM 33 followed by a treatment with DRAQ5 for 5 min at 37°C. On 
the image fluorescein is green and nuclei are blue. (B) Incorporation of the [3H]cholesterol anchor 35 to the 
membrane of SH-SY5Y cells. Cells were incubated with different concentration of 37 (grey bars) or 35 (black 
bars) in the presence of 10 μM β-cyclodextrin followed by liquid scintillation counting of the washed and 
trypsinized cells. The error bars represent SEM values of three parallel measurements. 
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method, and it was applied for studying the cell membrane incorporation of 35. SH-SY5Y 
cells were incubated with 1 – 100 nM of 35 or 37 at 37ºC for 10 and 30 min, and then cells 
were washed and trypsinized. The membrane incorporated radioactivity was determined by 
liquid scintillation counting of the filtered cells. It was found that 37 was not incorporated into 
the cell membranes, as the radioactivity of these cell populations was slightly above the 
background (Figure 28). However, when cells were treated with 35, concentration- and time-
dependent incorporation of the radioactive cholesterol anchor was observed. The radioactivity 
of the cell cultures was ca. 20% higher after 30 min incubation than after 10 min incubation 
indicating fast plasma membrane incorporation of 35. In order to calculate the membrane 
concentration of the [3H]cholesterol anchor, the concentration of cells was determined by a 
Bürker chamber and then the radioactivity per cell value was calculated. Using the specific 
activity of 35, it was found that 2×106 cholesterol anchor molecules were incorporated per cell 
in average when cells were treated with 100 nM 35 for 30 min. 
 
4.11. Protein anchoring to the plasma membrane with cell surface click reaction 
The semisynthesis of lipoproteins has inherent difficulties because the lipid part can initiate 
protein aggregation. For example the -sheet content of the PrP-20 conjugate was 4% higher 
as compared with the PrP as observed by CD spectroscopy. Furthermore, the purification of a 
protein-lipid conjugate can also be difficult. Therefore, an additional method was investigated 
for the C-terminal protein cholesterylation. In this two-step strategy, the C-terminus of the 
protein is modified with an alkyne followed by a CuAAC reaction with a membrane-
incorporated azido-cholesterol. Beyond the high reaction rate, bioorthogonality, and 
chemoselectivity the advantage of the CuAAC reaction for our purpose includes the 
hydrolytic and enzymatic stability of the azides, alkynes and the triazole product forming in 
the headgroup of the cholesterol anchor in live cell cultures.126-131 In order to demonstrate the 
procedure, the cell surface conjugation of the red fluorescent protein mCherry was performed. 
The fluorescence of this model protein is sensitive for structural changes, thus, it is indicative 
about the retention of the native protein structure after the lipidation and it can be detected by 
fluorescence microscopy in the target cell culture. Furthermore, a fluorescein-labelled Pra 
derivative was applied as an alkyne tag for the C-terminal modification of mCherry. This way 
a dual fluorescent protein-conjugate was obtained that is advantageous to demonstrate the  
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Figure 29. A) Introduction of the fluorescent alkyne 4 to the C-terminus of mCherry-Cys; a) 5 equ 4, 20 mM 
Tris, 10 mM TCEP, pH7.5, RT, 1h. B) SDS-PAGE: lane 1, molecular weight marker; lane 2, 38; lane 3, 4. 
presence of both the protein and the linker moiety on the cell surface. Furthermore, the 
unreacted azido-cholesterol does not contribute to the fluorescent signal that is directly 
assigned to the anchored protein. 
Tagging of the model protein mCherry was achieved via the Michael addition of mCherry-
Cys and the fluorescein-labelled maleimido alkyne 4. The conjugation was performed with a 
protein to maleimide ratio of 1:5, and the total amount of 4 was added in 5 portions over 1 h. 
The Michael addition was found to be fast and this way the quantitative conversion of 
mCherry-Cys was achieved. The mCherry-4 conjugate was separated from the linker excess 
by size exclusion chromatography. When the purified conjugate was analyzed by SDS-PAGE, 
it was found that it did not contain surplus fluorescent maleimido alkyne 4 (Figure 29). Under 
denaturing conditions, the acylimine group of the mCherry fluorophore is hydrolized185, 186 
that results in the appearance of additional bands with a Mw of 7.8 and 19.8 kDa. The bands 
corresponding to the full length mCherry-Cys and to the C-terminal mCherry-Cys fragment 
were found to be fluorescent under UV light that reveals the covalent attachment of the 
fluorescein-labelled alkyne 4 to the C-terminus of mCherry-Cys. Excitation and emission 
spectra of the mCherry-alkyne conjugate were recorded and the presence of both fluorophores 
was observed (Figure 30). 
In order to perform a CuAAC on the surface of live cells, the azido-cholesterol was first 
introduced into the plasma membrane of cultured SH-SY5Y human neuroblastoma cells. β-
cyclodextrin was used as a delivery vector, and the corresponding inclusion complex was 
prepared by incubating 30 µM of azido-cholesterol 11 and 75 μM of β-cyclodextrin overnight  
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Figure 30.  Excitation (─ λem= 518 nm; ─ λem= 610 nm) and emission (--- λex= 488 nm; --- λex= 543 nm; --- 
λex= 587 nm) spectra of 15 μM 38 in H2O at 25°C. 
in DMEM cell culture medium. Then cells were treated with a solution of the resulting 
azidolipid complex in serum-free medium for 30 min. It is important to note, that the normal 
cellular cholesterol level is not affected at a β-cyclodextrin concentration of 75 μM, because 
cholesterol extraction from the cell membrane requires much higher β-cyclodextrin 
concentration.179  
Parallel to the azido-cholesterol loading the copper catalyst was prepared by reducing 
CuSO4 (50 μM) with NaAsc (500 μM) in the presence of the accelerator ligand His (100 μM) 
over 15 min followed by the addition of the carbonyl-capturing reagent aminoguanidine (500 
μM). Finally the alkynes 4 or 38 were added (Figure 31). Cells were then washed and treated 
with the resulting alkyne solutions. The ligand accelerated CuAAC reactions performed on 
live cell surface were monitored by fluorescence microscopic imaging of the cells (Figure 
32). In control experiments cells were not pretreated with azido-cholesterol, but incubated 
with 4 or with 38 in the presence of the same catalyst and additives. These experiments 
resulted in no detectable fluorescent cell labelling even when 4 or 38 was applied at 100 μM 
concentration, and thus, evidenced that neither 4 nor 38 has non-specific adsorption on the 
surface of SH-SY5Y cells. When cells pretreated with the β-cyclodextrin inclusion complex 
of azido-cholesterol were incubated with 4, intensive green membrane fluorescence was 
observed indicating the successful cell surface CuAAC between the cholesterol azide and 4. 
Similarly, when the azido-cholesterol loaded cells were incubated with the dual fluorescent 
conjugate 38, intensive red and green fluorescence was detected on the cell surface.  
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Figure 31. Schematic representation of the cell surface CuAAC. SH-SY5Y cells were azido-cholesterol loaded 
with a (a) 30 µM 11–β-cyclodextrin inclusion complex-treatment in serum free medium, RT, 30 min, followed 
by incubation with (b) 30 µM 4, or (c) 60 µM 38 in the presence of 50 µM CuSO4, 500 µM NaAsc, 100 µM His, 
500 µM aminogunaidine, PBS (pH7.4), 30 min. 
 
Figure 32. Confocal laser scanning and differential interference contrast (right bottom) microscopy images of 
SH-SY5Y cells. Azido-cholesterol pretreated cells were incubated with 4 or with 38 in PBS pH 7.4 in the 
presence of 50 µM CuSO4, 500 µM NaAsc, 100 µM His and 500 µM aminoguanidine for 30 min. In control 
experiments SH-SY5Y cells were not pretreated with azido-cholesterol before their incubation with 4 or with 38 
under the same conditions. Cells were washed with PBS after the treatments and then incubated in fresh medium 
during the imaging. On the images fluorescein is green, mCherry is red and nuclei are blue, scale bars: 50 μm. 
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Accordingly, the mCherry protein C-terminally derivatized with the fluorescent alkyne 4 was 
covalently attached to azido-cholesterol. Furthermore, the cholesterol moiety of the resulting 
cholesteryl mCherry lipoprotein was able to anchor the attached protein to the plasma 
membrane. The red fluorescence of the anchored mCherry protein also indicated that the cell 
surface cholesteryl lipoprotein formation did not denature the protein. Finally, the in vitro 
cytotoxicity of 4 and 38 was investigated in an MTT assay, and it was found that they exerted 
no cytotoxic effects under the conditions of the applied cell surface CuAAC reaction. 
 
5. Summary 
 
The main goal of this work was to develop simplified GPI mimetic lipids and to establish a 
method for their protein conjugation and for the exogenous introduction of the semisynthetic 
lipoproteins to the plasma membrane of live cells. The resulting lipidated proteins are useful 
tools to investigate membrane anchored proteins, which have important role in the 
maintenance of the normal life functions as well as in some diseases. 
In order to achieve our goals, fluorescent cholesterol derivatives were designed and 
synthesized. The application of cholesterol as the membrane anchoring hydrophobic moiety of 
the GPI substitutes anticipates the direction of the protein conjugate to the cholesterol-rich 
lipid rafts, that is the accumulation platform of GPI-APs. In a convergent synthetic strategy 
propargyl glycine (Pra) was used as an orthogonal trifunctional linker to build up the 
headgroup of the cholesterol anchors, and separately, amphiphilic cholesterol derivatives were 
prepared from cholesteryl hemisuccinate and amino-oligo(ethylene glycol) azides. In order to 
obtain relevant GPI substitutes, the length of the polyether linker was chosen to be similar to 
that of the glycan core of the GPIs, because this hydrophilic moiety is responsible to expose 
the attached protein to the extracellular space. A fluorescent reporter and a Michael acceptor 
were introduced via the transformation of the amino and the carboxyl groups of Pra. The 
Michael acceptor was exploited for the conjugation with C-terminally Cys-extended proteins, 
while direct fluorescence microscopic studies of the membrane-associated cholesteryl 
lipoprotein conjugates required the small molecule fluorophores. Finally, the fluorescent 
anchors were assembled in an azide-alkyne cycloaddition. 
The physicochemical properties of the cholesterol anchors were optimized by the 
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introduction of three different fluorescent reporters (fluorescein, BODIPY and Cy5) with 
different polarities and spectral features. The usefulness of the anchors was estimated by 
fluorescence microscopic investigation of their capability to stain the plasma membrane of 
SH-SY5Y cells. The solubility of the cholesterol anchors in aqueous buffers was crucial both 
for the effective protein conjugation and for the exogenous introduction of the resulting 
cholesteryl lipoproteins into live cell membranes. It was found that the hydrophilic character 
of the fluorophore deeply affected the water solubility of the anchors, while increasing the 
length of the polar oligoether spacer had minor effect. The BODIPY-labelled cholesterol 
anchors exhibited the least solubility in polar solvents however homogeneous membrane 
staining was achieved when it was applied in a β-cyclodextrin inclusion complex. In the case 
of the fluorescein-labelled anchors homogeneous cell membrane staining was observed 
without the application of β-cyclodextrin when the phenol of the fluorescein moiety was 
converted into diisopropylammonium phenolate salt. However, the pH dependent 
fluorescence and the low photostability of fluorescein inspired us to consider the 
incorporation of sulfonated Cy5 which is highly polar and exceptionally bright. It was found 
that the Cy5-labelled cholesterol anchor resulted in an intensive homogeneous membrane 
staining at lower concentration than the fluorescein-labelled derivative. 
Two different Michael acceptors, a maleimide and a vinylsulfone were investigated for 
the protein conjugation. Their reactivity and selectivity differs, that is important when proteins 
requiring different buffer conditions for solubilization are to be lipidated. The Michael 
additions were optimized by using a Cys-containing model peptide, and it was found that the 
maleimide was more reactive at lower pH, while the vinylsulfone was more selective at higher 
pH toward the Cys thiol Michael donor. 
Before the application of the anchors for protein cell membrane delivery, the hydrolytic 
stability of the headgroup was also investigated. The crucial cholesteryl ester was found to be 
stable against hydrolysis at physiological pH. Furthermore, the membrane fluorescence 
remained constant during long-term incubation of the cell membrane incorporated fluorescent 
anchors suggesting that the headgroups of the anchors were not subjected to enzymatic 
hydrolysis. 
The protein conjugation of the fluorescent anchors was investigated via Michael addition 
to the C-terminally Cys extended, recombinant mCherry-Cys protein. mCherry is a red 
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fluorescent protein and its conjugation with a green fluorophore containing cholesterol anchor 
results in a dual fluorescent lipoprotein conjugate. When it is delivered into the cell 
membrane, the appearance of both red and green fluorescence on the plasma membrane are 
indicative of the successful membrane anchoring of the protein without significant change in 
the protein structure. The mCherry-Cys – cholesterol anchor addition resulted in a mixed 
micellar associate of the protein–anchor conjugate, because the amphiphilic cholesterol 
anchor dissolved in aqueous buffers in micellar form. A two-step purification method was 
then optimized to obtain cholesteryl-mCherry free of surplus anchor that included the 
application of β-cyclodextrin to disrupt the micellar associates. In the resulting β-cyclodextrin 
inclusion complex of cholesteryl mCherry, the lipid part of the conjugate remained soluble in 
cell culture media and the protein was not denatured. The purity of the dual fluorescent 
cholesteryl mCherry was evidenced by SDS-PAGE, and the preserved protein structure was 
revealed by CD spectroscopy. The confocal microscopy images, especially the colocalization 
of the green and red fluorescence confirmed that the mCherry protein was anchored to the 
plasma membrane of live cells via the green fluorescent cholesterol anchor. 
The most investigated GPI anchored protein, prion protein (PrP) was chosen to be 
modified using the synthetic cholesterol anchors and to investigate if cholesteryl PrP 
derivatives are appropriate for cell membrane delivery. Therefore, the recombinant full length 
mouse PrP was conjugated to cholesterol anchors and after an optimized semisynthesis and 
purification, the introduction of the cholesteryl-mPrP into the plasma membrane of live 
neuroblastoma cells was achieved. 
In order to quantitate the cell membrane delivered cholesteryl lipoproteins, a tritium 
labelled cholesterol anchor was prepared. Similarly to the fluorescent labelling, the 
radioactive reporter was introduced into the headgroup of the anchor. When SH-SY5Y cells 
were incubated with the [3H]cholesterol anchor, a concentration and time dependent 
membrane incorporation was observed. 
In order to eliminate the cholesteryl lipoprotein purification steps from our strategy and to 
minimize the risk of the protein denaturation, an alternative convergent semisynthetic method 
was investigated. This method is a cell surface application of the CuAAC reaction including 
the conjugation of a maleimido fluorescent Pra linker to the protein C-terminus followed by a 
cycloaddition through the alkyne to an azido cholesterol pre-incorporated into the cell 
47 
 
membrane. This way the target fluorescent cholesteryl lipoprotein was formed in situ on the 
surface of live cells. Similarly to the β-cyclodextrin-mediated membrane delivery, surplus 
detergents or unreacted fluorescent lipids were not introduced into the plasma membrane, and 
thus, the fluorescent signal is unambiguously associated with the cell surface-prepared 
cholesteryl lipoprotein. By using this method the red fluorescent protein, mCherry was 
successfully anchored to the plasma membrane of live cells without change of its fluorescent 
properties. The application of His and aminoguanidine as accelerator ligands protected live 
cells from the cytotoxic effects of the CuAAC catalyst components, and under these 
conditions the mCherry protein was not significantly denatured. 
Altogether, in this thesis complete protein cell membrane anchoring strategies were 
developed for the structural and functional investigation of the cell membrane anchored PrP 
and other GPI-APs. 
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ABSTRACT: The exogenous introduction of ﬂuorescent
lipoproteins into cell membranes is a method for visualizing
the cellular traﬃc of membrane associated proteins, and also
for altering the cell surface in a controlled manner. In order to
achieve the cell membrane anchoring of proteins and their
subsequent ﬂuorescence based detection, a cholesterol
derivative was designed. The headgroup of the novel
cholesterol anchor contains a ﬂuorescent reporter and a thiol
reactive maleimide for protein conjugation. Protein conjuga-
tion was demonstrated by the addition of a green ﬂuorescent
maleimido anchor to the C-terminus of a Cys extended red
ﬂuorescent protein, mCherry. The resulting dual ﬂuorescent
cholesteryl lipoprotein was successfully separated from the
micellar associates of the surplus ﬂuorescent lipid anchor without denaturing the protein, and the lipoprotein containing only the
covalently linked, stoichiometric ﬂuorescent lipid was eﬃciently delivered to the plasma membrane of live cells. It was
demonstrated that the membrane ﬂuorescence could be directly assigned to the protein−anchor conjugate, because no excess of
ﬂuorescent lipid species were present during the imaging experiment and the protein and anchor ﬂuorescence colocalized in the
cell membrane. Molecular dynamics simulations and subsequent trajectory analysis suggest also the spontaneous and stable
membrane association of the cholesterol anchor. Thus, the method could be beneﬁcially applied for studying membrane
associated proteins and for preparing mimetics of glycosylphosphatidylinositol (GPI)-anchored proteins to target cholesterol-rich
membrane microdomains.
■ INTRODUCTION
Lipidation plays an important role in the localization and
function of proteins. Four common modiﬁcations of proteins
with lipid moieties are myristoylation, palmitoylation, prenyla-
tion, and the attachment of glycosylphosphatidylinositol (GPI)
anchors.1−6 The amidation of the protein C-terminus with a
GPI glycolipid results in proteins tethered to the extracellular
leaﬂet of the cell membrane.7−9 This modiﬁcation is widespread
throughout eukaryotes, and more than 150 human GPI-
anchored proteins (GPI-APs) are known with various
functions: enzymes, receptors, complement regulation proteins,
antigens, or adhesion molecules.10 Beyond the normal
physiological functions, GPI-APs are associated with a range
of diseases including paroxysmal nocturnal hemoglobinuria,
prion diseases, carcinogenesis, and sleeping sickness.11−14 The
important functional role of the GPI-APs is further evidenced
by the embryonic lethality of the GPI-deﬁcient mice.15 The
GPI glycolipids have the conserved Man(α1−2)Man(α1−
6)Man(α1−4)GlcN(α1−6)myoIno glycan core and variations
arise in the substitution pattern and in the lipid composi-
tion.10,16 The lipid part of the mammalian GPIs is
phosphatidylinositol with stearyl chains; therefore, the GPI-
APs are able to temporarily associate with sphingolipid- and
cholesterol-rich membrane microdomains, i.e., lipid rafts.7,16−21
This clustering is mainly due to the favorable hydrophobic
interactions between the saturated acyl chains of the GPI
anchor and the lipid constituents of the rafts.7,17 It was
evidenced that the lipid raft association of the GPI-APs could
be abrogated by cholesterol depletion of the cell membrane and
by replacing the GPI moiety with a transmembrane anchor.22
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The accumulation of the GPI-APs in lipid rafts may serve as
platforms for diverse cellular functions (e.g., signal trans-
duction) by promoting protein−protein interactions.23,24
Beyond the membrane anchoring, other biological functions
of the GPIs associated with the carbohydrate moiety are rather
unknown, partly because the complexity of the GPIs restricts
the preparation of GPI-AP derivatives for structural and
functional studies. However, a few studies have been published
on the semisynthesis of proteins with simpliﬁed anchors, and
on their subsequent delivery to membrane structures,25−34 and
it was shown that the removal of the carbohydrate moiety or its
truncation does not interfere with the anchoring function of the
GPI.35
An important feature of the GPI-APs is that they
spontaneously reintegrate into model lipid membranes, or
live cell membranes with the retention of the biological
function.36−44 This property of the GPI-APs may be exploited
for structural and functional studies, because semisynthetic
lipoproteins containing GPI anchor mimetic lipids can also be
introduced into cell membranes by exogenous addition. Since
cholesterol prefers the interaction with sphingolipids in the cell
membrane, it has the potential to target the attached protein to
lipid rafts.20,21 This type of lipid anchor is found in the matured
Hh and Shh proteins of the hedgehog family as a C-terminal
cholesteryl ester.45−48 Furthermore, in the case of a semi-
synthetic peptidyl cholesterol−Ras protein conjugate, choles-
terol was reported to anchor the conjugated protein to the cell
membrane.49 Other cholesterol derivatives, such as 3β-
cholesterylamine and 3β-cholesterylcarbamate, were also
reported as membrane anchors of artiﬁcial membrane
receptors.50−56
Here, we report on the development of a ﬂuorescent
cholesterol anchor as a GPI mimetic, and on its insertion into
the plasma membrane of live cells. Fluorescent labeling is
generally required when the cellular traﬃc of a membrane
protein is to be monitored, and that is usually achieved by
fusion of a ﬂuorescent reporter protein to the target protein.
However, the size of the reporter protein is frequently
comparable to that of the target protein, and it can perturb
the biophysical and biochemical characteristics of the target
protein. In order to avoid this drawback, our approach utilizes a
small molecule ﬂuorophore for facilitating the imaging of
membrane anchored proteins. The ﬂuorescent reporter is
introduced into the headgroup of the membrane anchor;
therefore, its interference with the lipid chains in the cell
membrane is unlikely. Furthermore, it might have minimal
eﬀect on protein−protein interactions between the membrane
anchored protein and other cell surface proteins. This anchor
was used for the semisynthesis of a cholesteryl lipoprotein to
demonstrate the usefulness of this protein lipidation approach.
Before imaging applications, the separation of the semisynthetic
ﬂuorescent lipoprotein from the micellar associates of the
amphiphilic ﬂuorescent lipids without denaturing the native
fold of the protein is a crucial step. When it is achieved, the
ﬂuorescence of the cholesterol anchor can be unambiguously
assigned to the attached protein, and thus, the protein can be
visualized after cell membrane delivery of the semisynthetic
construct. On the whole, our method can be utilized for
imaging the cellular traﬃc of lipoproteins and also for
investigating protein−protein interactions on the cell surface.
■ EXPERIMENTAL SECTION
Synthesis of the Cholesterol Probe. Cholesteryl 1-
(Triphenylmethylamino)-15-oxo-4,7,10-trioxa-14-azaocta-
decan-18-oate (1). Cholesteryl hemisuccinate (150 mg, 0.31
mmol) and TBTU (100 mg, 0.31 mmol) were dissolved in 10
mL of CHCl3/CH2Cl2 (4:1), and DIEA (68 μL, 0.40 mmol)
was added. After 5 min activation 1-(triphenylmethylamino)-
13-amino-4,7,10-trioxa-tridecane (143 mg, 0.31 mmol) was
added to the solution. The mixture was stirred for 8 h at RT,
then it was evaporated in vacuo. The crude product was
puriﬁed by column chromatography (CHCl3/MeOH (99:1))
to give 274.6 mg (95%) of 1 as a white solid. Rf 0.5 (CHCl3/
MeOH = 99:1); k′ = 4.63 (tR = 20.05 min; Alltech Alltima HP
C18 column (250 × 4.6 mm, 5 μm), isocratic elution with
ACN/MeOH 15:85, ﬂow rate: 1 mL/min, λ = 215 nm); [α]D
20
= −10.0 (c = 1.1, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.47
(d, 6H, J = 7.5 Hz, Trt-o-H), 7.26 (t, 6H, J = 7.5 Hz, Trt-m-H),
7.17 (t, 3H, J = 7.2 Hz, Trt-p-H), 6.31 (t, 1H, J = 5.0 Hz, amide
NH), 5.36 (d, 1H, J = 3.0 Hz, 6-H), 4.60 (m, 1H, 3α-H), 3.57
(m, 12H, 34-H, 35-H, 36-H, 37-H, 38-H, 39-H), 3.35 (q, 2H, J
= 5.8 Hz, 32-H), [2.61 (t, 2H, J = 6.9 Hz), 2.42 (t, 2H, J = 6.9
Hz)] (29-H, 30-H), 2.31 (d, 2H, J = 7.8 Hz, 4-H), 2.22 (t, 2H, J
= 5.5 Hz, 41-H), 2.01 (m, 1H, 12β-H), 1.98 (m, 1H, 7β-H),
1.84 (m, 3H, (1β-H, 2α-H, 16α-H)), 1.76 (m, 4H, 33-H, 40-
H), [1.64−1.04 (m, 18H): 2β-H, 12α-H, 15α/β-H, 1.55 (7α-
H), 1.52 (25-H), 1.46 (11α/β-H), 1.42 (8β-H), 1.35 (23-H),
1.33 (20-H, 22-H), 1.23 (16β-H), 1.18 (23-H′), (1.14, 1.09)
(1α-H, 17α-H), 1.12 (24-H2)], [1.04−0.90 (m, 3H): 0.96
(14α-H, 22-H′), 0.92 (9α-H)], 1.01 (s, 3H, 19-H), 0.92 (d, 3H,
J = 6.3 Hz, 21-H), [0.88 (d, 3H, J = 1.5 Hz), 0.86 (d, 3H, J =
1.5 Hz)] (26-H, 27-H), 0.68 (s, 3H, 18-H); 13C NMR (125
MHz, CDCl3) δ 172.5 (ester CO), 171.4 (amide CO), 146.4
(Ph Cq), 139.7 (C-5), 128.8 (Ph o-CH), 127.9 (Ph m-CH),
126.3 (Ph p-CH), 122.7 (C-6), 74.3 (C-3), 71.0 (CPh3), [70.7
(2C), 70.4, 70.2 (3C)] (C-34, C-35, C-36, C-37, C-38, C-39),
(56.8, 56.3) (C-14, C-17), 50.2 (C-9), 42.4 (C-13), 41.1 (C-
41), 39.9 (C-12), 39.6 (C-24), 38.2 (2C, C-4, C-32), 37.1 (C-
1), 36.7 (C-10), 36.3 (C-22), 35.9 (C-20), 32.1 (C-7), 32.0 (C-
8), (31.2, 30.1) (C-29, C-30), 30.7 (C-40), 29.0 (C-16), 28.4
(C-33), 28.1 (C-25), 27.9 (C-2), 24.4 (C-15), 24.0 (C-23),
(22.9, 22.7) (C-26, C-27), 21.2 (C-11), 19.4 (C-19), 18.9 (C-
21), 12.0 (C-18); MS(MALDI) calcd for C60H86N2O6 930.65,
found 931.67 [M+H]+, 689.52 [(M−Trt)+2H]+; ATR FT-IR
3310, 3082, 3055, 3028, 2933, 2866, 1728, 1641, 1547, 1489,
1447, 1171, 1107, 1029, 1001, 772, 745, 706, 644, 623 cm−1.
Cholesteryl 1-Amino-15-oxo-4,7,10-trioxa-14-azaoctade-
can-18-oate (2). The tritylamine 1 (145 mg, 0.16 mmol)
was dissolved in 5 mL of CH2Cl2 containing 10% (v/v) TFA
and 5% (v/v) triisopropylsilane, and it was stirred for 10 min.
The solution was evaporated in vacuo and the cleavage was
repeated four times. The product was puriﬁed by column
chromatography (AcOH/MeOH (2:98)) to give 120.7 mg
(94%) of pure 2 as a pale yellow solid. Rf 0.52 (AcOH/MeOH
= 2:98); k′ = 3.71 (tR = 16.77 min, Alltech Alltima HP C18
column (250 × 4.6 mm, 5 μm), isocratic elution with ACN/
MeOH 15:85, ﬂow rate: 1 mL/min, λ = 215 nm);
MS(MALDI) calcd for C41H72N2O6 688.54, found 689.54 [M
+H]+.
Cholesterol Probe (3). The amine 2 (91 mg, 0.11 mmol)
was dissolved in 5 mL of DMF and then DIEA (19 μL, 0.11
mmol) was added. The solution of ﬂuorescein-5-isothiocyanate
(51 mg, 0.13 mmol) and DIEA (57 μL, 0.33 mmol) in 1.5 mL
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DMF was added in three portions over 6 h at RT. Then, it was
evaporated in vacuo and the crude product was puriﬁed by
column chromatography (CHCl3/acetone/AcOH 60:39:1)
followed by (CHCl3/MeOH/AcOH 94:5:1) to give 55.6 mg
(47%) of pure 3 as an orange solid. Rf 0.54 (CHCl3/acetone/
AcOH = 60:39:1), 0.36 (CHCl3/MeOH/AcOH = 94:5:1); k′ =
1.25 (tR = 7.95 min; Alltech Alltima HP C18 column (250 ×
4.6 mm, 5 μm), isocratic elution with ACN/MeOH 15:85, ﬂow
rate: 1 mL/min, λ = 215 nm); [α]D
20 = −9.4 (c = 0.32, CHCl3);
1H NMR (500 MHz, (CD3)2SO) δ 10.17 (brs, Ar−OH), 9.95
(brs, 1H, CS-NH-Ar), 8.23 (s, 1H, 4′-H), 8.10 (brs, 1H, CS-
NH-CH2), 7.79 (t, 1H, J = 5.3 Hz, CO-NH), 7.73 (d, 1H, J =
5.3 Hz, 6′-H), 7.14 (d, 1H, J = 8.2 Hz, 7′-H), 6.65 (d, 2H, J =
1.4 Hz, 4″-H), 6.59 (d, 2H, J = 8.6 Hz, 1″-H), 6.54 (dd, 2H, J =
8.7 Hz, 1.6 Hz, 2″-H), 5.30 (s, 1H, 6-H), 4.42 (m, 1H, 3-H),
3.50 (m, 10H, 35-H, 36-H, 37-H, 38-H, 41-H), 3.36 (m, 4H,
34-H, 39-H), 3.06 (q, 2H, J = 6.4 Hz, 32-H), 2.44 (t, 2H, J =
6.7 Hz, 30-H), 2.30 (t, 2H, J = 6.7 Hz, 29-H), 2.22 (d, 2H, J =
7.5 Hz, 4-H), 1.90 (m, 2H, 7β-H, 12β-H), 1.80 (quin, 2H, J =
6.5 Hz, 40-H), 1.75 (m, 3H, 1β-H, 2α-H, 16α-H), 1.59 (quin,
2H, J = 6.5 Hz, 33-H), [1.55−0.89 (m, 21H): 1.50 (2β-H, 15α-
H), 1.48 (7α-H), 1.46 (25-H), 1.45 (11-α/β-H), 1.36 (8β-H),
1.30 (22-H, 23-H), 1.29 (20-H), 1.20 (16β-H), 1.10 (23-H′),
1.09 (12α-H, 15β-H, 24-H2), (1.05, 0.95) (14α-H, 17α-H),
1.01 (1α-H), 0.95 (22-H′), 0.89 (9α-H)], 0.94 (s, 3H, 19-H),
0.86 (d, 3H, J = 6.2 Hz, 21-H), [0.82 (d, 3H, J = 1.6 Hz), 0.81
(d, 3H, J = 1.6 Hz)] (26-H, 27-H), 0.62 (s, 3H, 18-H); 13C
NMR (125 MHz, (CD3)2SO) δ 180.5 (CS), 171.7 (ester CO),
170.6 (amide CO), 168.5 (lactone CO), (159.7, 152.0) (C-3″,
C-4″a), (146.8, 141.4) (C-5′, C-8′), 139.5 (C-5), 129.2 (C-6′),
129.0 (C-1″), 126.7 (C-3′), 124.0 (C-7′), 122.1 (C-6), 116.4
(C-4′), 112.7 (C-2″), 109.9 (C-1″a), 102.3 (C-4″), 83.5 (C-
9″), 73.2 (C-3), [69.8 (2C), 69.6 (2C)] (C-35, C-36, C-37, C-
38), (68.2, 68.1) (C-34, C-39), (56.2, 55.7) (C-14, C-17), 49.5
(C-9), 41.9 (C-13), 41.4 (C-41), 39.2 (C-12), 39.0 (C-24),
37.7 (C-4), 36.5 (C-1), 36.1 (C-10), 35.9 (C-32), 35.7 (C-22),
35.3 (C-20), 31.4 (C-8), 31.3 (C-7), 30.0 (C-29), 29.4 (2C, C-
30, C-33), 28.6 (C-40), 27.8 (C-16), 27.4 (C-25), 27.3 (C-2),
23.9 (C-15), 23.3 (C-23), (22.7, 22.4) (C-26, C-27), 20.6 (C-
11), 19.0 (C-19), 18.6 (C-21), 11.7 (C-18); MS(MALDI) calcd
for C62H83N3O11S 1077.57, found 1078.58 [M+H]
+; ATR FT-
IR 3600−2400 br, 3300, 3092, 2934, 2866, 1730, 1611, 1587,
1539, 1504, 1464, 1447, 1375, 1331, 1254, 1213, 1171, 1109,
1078, 1024, 993, 849, 824, 787, 671 cm−1.
Investigation of the in Vitro Hydrolytic Stability of the
Cholesteryl Ester in Probe 3. The cholesterol probe 3 (150
μM) was dissolved in PBS buﬀer containing 5% (v/v) HFIP.
Samples were taken over a period of 24 h and were analyzed by
RP-HPLC on an Alltech Alltima HP C18 column (250 × 4.6
mm, 5 μm) with isocratic elution (ACN/MeOH 15:85) at a
ﬂow rate of 1 mL/min, λ = 216 nm. The probe 3 peak area
values of the samples were compared to that of the starting
solution.
Synthesis of the Cholesterol Anchor. (S)-N-(2-Maleimi-
doethyl)-2-(tert-butoxycarbonylamino)pent-4-ynamide (4).
N-(2-(tert-butoxycarbonylamino)-ethyl)-maleimide (100 mg,
0.41 mmol) was dissolved in 10 mL of TFA/CH2Cl2 1:1 and
the solution was stirred for 30 min, then it was evaporated in
vacuo. The resulting N-(2-aminoethyl)maleimide triﬂuoroace-
tate was used without further puriﬁcation. Boc-Pra-OH (81.3
mg, 0.38 mmol) and HOBt (58.2 mg, 0.38 mmol) were
dissolved in THF (6 mL) and DIC (58.8 μL, 0.38 mmol) was
added. After 5 min stirring N-(2-aminoethyl)maleimide
triﬂuoroacetate (96.6 mg, 0.38 mmol) and DIEA (65 μL,
0.38 mmol) in THF (1 mL) were added, and the reaction
mixture was stirred for 8 h at RT. It was diluted with 20 mL of
EtOAc and then extracted with 0.5 M HCl (3 × 20 mL). The
combined organic layer was dried over Na2SO4 and evaporated
in vacuo. The crude product was puriﬁed by column
chromatography (CHCl3/acetone 4:1) to give 114.5 mg
(90%) of pure 4 as a white solid. Rf 0.4 (CHCl3/acetone
4:1); k′ = 3.86 (tR = 17.0 min; Alltech Alltima HP C18 column
(250 × 4.6 mm, 5 μm), linear gradient of 5→95% B in A over
30 min (eluent A: 0.1% (v/v) TFA in H2O, eluent B: 0.08% (v/
v) TFA in ACN), ﬂow rate: 1 mL/min, λ = 216 nm); [α]D
20 =
−2.6 (c = 1, CHCl3); 1H NMR (500 MHz, (CD3)2SO) δ 8.06
(t, 1H, J = 5.2 Hz, amide NH), 6.98 (s, 2H, maleimide CH),
6.81 (d, 1H, J = 8.5 Hz, carbamate NH), 3.95 (dt, 1H, J = 8.5,
4.5 Hz, α-H), 3.43 (t, 2H, J = 5.7 Hz, 1-H), 3.30 (m, 1H, 2-H),
3.10 (m, 1H, 2-H′), 2.77 (s, 1H, δ-H), 2.44 (ddd, 1H, J = 16.7,
4.5, 2.5 Hz, β-H), 2.32 (ddd, 1H, J = 16.7, 9.1, 1.6 Hz, β-H′),
1.36 (s, 9H, Boc-CH3);
13C NMR (125 MHz, (CD3)2SO) δ
171.0 (maleimide CO), 170.5 (Pra CO), 155.1 (carbamate
CO), 134.5 (maleimide CH), 81.0 (C-γ), 78.2 (C(CH3)3), 72.6
(C-δ), 53.2 (C-α), [37.0, 36.9] (C-1, C-2), 28.2 (CH3), 21.8
(C-β); MS(ESI) calcd for C16H21N3O5 335.15, found 335.90
[M+H]+, FT-IR (KBr) 3341, 3323, 3273, 3098, 2968, 2926,
2874, 2855, 2116, 1703, 1688, 1661, 1616, 1574, 1560, 1531,
1464, 1418, 1387, 1362, 1325, 1273, 1252, 1171, 1130, 1105,
1053, 961, 866, 826, 804, 686 (br) cm−1.
(S)-N-(2-Maleimidoethyl)-2-aminopent-4-ynamide (5). Nα-
t-Butyloxycarbonyl-propargyl-glycine-N-(2-maleimidoethyl)-
amide (4) (20.0 mg, 60 μmol) was dissolved in 2 mL of TFA/
CH2Cl2 1:1 and it was stirred for 30 min. The solution was
evaporated in vacuo to give 20.1 mg (96%) of pure 5 as a pale
yellow solid. Rf 0.4 (CHCl3/MeOH 95:5); HPLC: k′ = 1.23 (tR
= 7.8 min; Alltech Alltima HP C18 column (250 × 4.6 mm, 5
μm), linear gradient of 5→95% B in A over 30 min (eluent A:
0.1% (v/v) TFA in H2O, eluent B: 0.08% (v/v) TFA in ACN),
ﬂow rate: 1 mL/min, λ = 216 nm); MS(ESI) calcd for
C11H13N3O3 235.10, found 236.20 [M+H]
+.
( S ) - 2 - ( 3 - ( 5 - F l u o r e s c e i n y l - t h i o u r e i d o ) - N - ( 2 -
maleimidoethyl)pent-4-ynamide (6). Propargyl-glycine-N-(2-
maleimidoethyl)amide (5) (20.1 mg, 57.6 μmol) was dissolved
in THF (0.5 mL) and then ﬂuorescein-5-isothiocyanate (23.4
mg, 60 μmol) and DIEA (10.3 μL, 60 μmol) were added to the
solution; then, it was stirred for 13 h. After evaporation in
vacuo the crude product was puriﬁed by HPLC (Vydac
218TP1010 column (250 × 10 mm, 10 μm), linear gradient of
5→95% B in A over 30 min (eluent A: 0.1% (v/v) TFA in
H2O, eluent B: 0.08% (v/v) TFA in ACN), ﬂow rate: 4 mL/
min, λ = 216 nm) to give 25.8 mg (69%) of pure 6 as an orange
solid. Rf 0.4 (CHCl3/MeOH 95:5); HPLC: k′ = 4.31 (tR = 18.6
min; Alltech Alltima HP C18 column (250 × 4.6 mm, 5 μm),
linear gradient of 5→95% B in A over 30 min (eluent A: 0.1%
(v/v) TFA in H2O, eluent B: 0.08% (v/v) TFA in ACN), ﬂow
rate: 1 mL/min, λ = 216 nm); [α]D
20 = −3.9 (c = 0.7, MeOH);
1H NMR (500 MHz, (CD3)2SO) δ 10.41 (brs, 1H, CS-NH-
Ar), 10.10 (brs, Ar-OH), 8.44 (s, 1H, 4′-H), 8.37 (t, 1H, J = 5.8
Hz, CONH), 8.14 (d, 1H, J = 7.4 Hz, CS-NH-Cα), 7.77 (dd,
1H, J = 8.3, 1.6 Hz, 6′-H), 7.18 (d, 1H, J = 8.3 Hz, 7′-H), 7.00
(s, 2H, maleimide CH), 6.66 (d, 2H, J = 1.9 Hz, 4″-H), 6.59 (d,
2H, J = 8.2 Hz, 1″-H), 6.55 (dd, 2H, J = 8.7, 2.0 Hz, 2″-H),
4.88 (q, 1H, J = 5.6 Hz, α-H), 3.48 (m, 2H, 1-H), 3.33 (m, 1H,
2-H), 3.27 (m, 1H, 2-H′), 2.85 (t, 1H, J = 2.4 Hz, δ-H), 2.80
(ddd, 1H, J = 17.0, 5.2, 2.4 Hz, β-H), 2.62 (ddd, 1H, J = 17.0,
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5.1, 2.3 Hz, β-H′); 13C NMR (125 MHz, (CD3)2SO) δ 179.8
(CS), 171.1 (maleimide CO), 169.5 (CONH), 168.6 (lactone
CO), (159.5, 151.9) (C-3″, C-4″a), (147.3, 141.3) (C-5′, C-8′),
134.6 (maleimide CH), 129.2 (C-6′), 129.1 (C-1″), 126.5 (C-
5′), 124.1 (C-7′), 116.2 (C-4′), 112.6 (C-2″), 109.7 (C-1″a),
102.3 (C-4″), 79.9 (C-δ), 73.7 (C-γ), 55.3 (C-α), 37.0 (2C, C-
1, C-2), 22.1 (C-β); MS(ESI) calcd for C32H24N4O8S 624.13,
found 625.00 [M+H]+; FT-IR (KBr) 3433 br, 3267 (br), 3065,
2995, 2884, 2822, 2683, 2560, 1744, 1680, 1639, 1612, 1589,
1578, 1510, 1460, 1425, 1317, 1287, 1206, 1182, 1136, 1113,
783, 739 cm−1.
Cholesteryl 1-Azido-13-oxo-3,6,9-trioxa-12-azahexade-
can-16-oate (7). Cholesteryl hemisuccinate (200 mg, 0.41
mmol) and TBTU (171 mg, 0.53 mmol) were dissolved in 6
mL of CHCl3/CH2Cl2 (4:1), and DIEA (91.3 μL, 0.53 mmol)
was added. It was stirred for 5 min, then 1-amino-11-azido-
3,6,9-trioxaundecane (89.5 mg, 0.41 mmol) was added to the
solution. The mixture was stirred for 8 h at RT, then it was
evaporated in vacuo. The crude product was puriﬁed by column
chromatography with CHCl3/MeOH (97:3) to give 253.5 mg
(90%) of 7 as a white solid. Rf 0.40 (CHCl3/MeOH = 97:3);
k′(HPLC) = 2.33 (tR = 14.5 min; Alltech Alltima HP C18
column (250 × 4.6 mm, 5 μm), isocratic elution with ACN/
MeOH (15:85), ﬂow rate: 1 mL/min, λ = 216 nm); [α]D
20 =
−26.0 (c = 1.7, CHCl3); 1H NMR (500 MHz, CDCl3) δ 6.20
(brs, 1H, NH), 5.36 (d, 1H, J = 3.3 Hz, 6-H), 4.61 (m, 1H, 3α-
H), 3.68 (m, 8H, 34-H, 35-H, 36-H, 37-H), 3.63 (m, 2H, 38-
H), 3.55 (t, 2H, J = 4.9 Hz, 33-H), 3.45 (q, 2H, J = 4.6 Hz, 32-
H), 3.40 (t, 2H, J = 4.7 Hz, 39-H), [2.64 (t, 2H, J = 6.8 Hz),
2.48 (t, 2H, J = 6.8 Hz)] (29-H, 30-H), 2.31 (d, 2H, J = 7.7 Hz,
4-H), 2.03 (m, 1H, 12β-H), 1.96 (m, 1H, 7β-H), 1.89 (m, 1H,
2α-H), 1.87 (m, 1H, 1β-H), 1.83 (m, 1H, 16α-H), [1.62−1.04
(m, 18H): 1.56 (2β-H, 15α-H), 1.53 (7α-H), 1.52 (25-H), 1.47
(11α/β-H), 1.44 (8β-H), 1.36 (23-H), 1.34 (20-H, 22-H), 1.20
(16β-H), 1.17 (23-H′), 1.15 (12α-H), 1.12 (1α-H), 1.11 (24-
H2), 1.09 (17α-H), 1.06 (15β-H)], 1.01 (s, 3H, 19-H), [1.03−
0.90 (m, 3H): 0.99 (14α-H, 22-H′), 0.94 (9α-H)], 0.91 (d, 3H,
J = 6.7 Hz, 21-H), [0.86 (d, 3H, J = 1.9 Hz), 0.85 (d, 3H, J =
1.9 Hz)] (26-H, 27-H), 0.67 (s, 3H, 18-H); 13C NMR (125
MHz, CDCl3) δ 172.2 (ester CO), 171.4 (amide CO), 139.6
(C-5), 122.6 (C-6), 74.3 (C-3), [70.7, 70.6, 70.5, 70.3, 70.0,
69.8] (C-33, C-34, C-35, C-36, C-37, C-38), 56.7 (C-14), 56.1
(C-17), 50.7 (C-39), 50.0 (C-9), 42.3 (C-13), 39.7 (C-12),
39.5 (C-24), 39.3 (C-32), 38.1 (C-4), 37.0 (C-1), 36.6 (C-10),
36.2 (C-22), 35.8 (C-20), 31.9 (C-7), 31.8 (C-8), [31.0, 29.9]
(C-29, C-30), 28.2 (C-16), 28.0 (C-25), 27.7 (C-2), 24.3 (C-
15), 23.8 (C-23), [22.8, 22.6] (C-26, C-27), 21.0 (C-11), 19.3
(C-19), 18.7 (C-21), 11.8 (C-18); MS(MALDI) calcd for
C39H66N4O6 686.50, found 687.62 [M+H]
+, 659.57 [(M-
N2)+H]
+; ATR FT-IR 3314, 2951, 2930, 2866, 2104, 1730,
1647, 1547, 1466, 1441, 1375, 1366, 1327, 1304, 1283, 1254,
1171, 1124, 1028, 999, 627, 530 cm−1.
Cholesterol Anchor (8). The alkyne 6 (42 mg, 67.2 μmol)
and the azide 7 (46 mg, 67.2 μmol) were dissolved in tBuOH
(0.9 mL). The solution of L(+)-ascorbic acid sodium salt (7.9
mg, 39.9 μmol) and CuSO4·5H2O (5.0 mg, 20.1 μmol) in 0.9
mL of water were added and the reaction mixture was stirred
for 48 h at RT. Then it was evaporated in vacuo and the crude
product was puriﬁed by column chromatography (CHCl3/
MeOH/AcOH 90:9:1) to give 58 mg (66%) of pure 8 as an
orange solid. Rf 0.4 (CHCl3/MeOH/AcOH 90:9:1); k′ = 5.20
(tR = 12.4 min; Vydac 214TP5410 C4 column (100 × 4.6 mm,
5 μm), linear gradient of 50→95% B in A over 25 min (eluent
A: 0.1% (v/v) TFA in H2O, eluent B: 0.08% (v/v) TFA in
ACN), ﬂow rate: 1 mL/min, λ = 216 nm); [α]D
20 = −32.9 (c =
0.65, CHCl3);
1H NMR (500 MHz, (CD3)2SO) δ 10.31 (s, 1H,
CS-NH-Ar), 10.19 (brs, Ar-OH), 8.39 (s, 1H, 4″-H), 8.32 (t,
1H, J = 5.6 Hz, α-CONH), 8.10 (d, 1H, J = 5.3 Hz, CS-NH-
Cα), 7.87 (t, 1H, J = 5.3 Hz, 32-NH), 7.79 (s, 1H, triazole
CH), 7.74 (d, 1H, J = 8.2 Hz, 6″-H), 7.15 (d, 1H, J = 8.2 Hz,
7″-H), 7.00 (s, 2H, maleimide CH), 6.64 (s, 2H, 4‴-H), 6.59
(dd, 2H, J = 8.6, 2.6 Hz, 1‴-H), 6.53 (dd, 2H, J = 8.6, 1.6 Hz,
2‴-H), 5.30 (d, 1H, J = 3.2 Hz, 6-H), 5.04 (q, 1H, J = 5.9 Hz,
α-H), 4.47 (t, 2H, J = 5.0 Hz, 39-H), 4.41 (m, 1H, 3-H), 3.76
(t, 2H, J = 5.0 Hz, 38-H), 3.47 (m, 2H, 1′-H), 3.44 (brs, 8H,
34-H, 35-H, 36-H, 37-H), 3.35 (t, 2H, J = 5.9 Hz, 33-H), 3.28
(m, 1H, 2′-H), 3.22 (dd, 1H, J = 14.0, 6.3 Hz, 2′-H′), 3.16 (q,
2H, J = 5.7 Hz, 32-H), 3.15 (m, 1H, β-H), 3.03 (dd, 1H, J =
14.9, 7.1 Hz, β-H′), [2.43 (t, 2H, J = 6.6 Hz), 2.31 (t, 2H, J =
6.7 Hz)] (29-H, 30-H), 2.22 (d, 2H, J = 7.6 Hz, 4-H), 1.93 (m,
1H, 12β-H), 1.87 (m, 1H, 7β-H), 1.75 (m, 3H, 1β-H, 2α-H,
16α-H), [1.56−0.89 (m, 21H): 1.50 (2β-H, 15α-H), 1.47 (7α-
H), 1.46 (25-H), 1.45 (11-α/β-H), 1.36 (8β-H), 1.30 (20-H,
22-H, 23-H), 1.19 (16β-H), 1.12 (23-H′), 1.09 (12α-H, 15β-H,
24-H2), 1.05 (17α-H), 0.96 (14α-H), 1.00 (1α-H), 0.97 (22-
H′), 0.88 (9α-H)], 0.94 (s, 3H, 19-H), 0.87 (d, 3H, J = 6.4 Hz,
21-H), [0.83 (d, 3H, J = 2.0 Hz), 0.82 (d, 3H, J = 2.0 Hz)] (26-
H, 27-H), 0.62 (s, 3H, 18-H); 13C NMR (125 MHz,
(CD3)2SO) δ 180.0 (CS), 171.7 (ester CO), 171.1 (maleimide
CO), 170.8 (30-CO), 170.4 (α-CO), 168.6 (lactone CO),
(159.8, 152.1) (C-3‴, C-4‴a), (147.2, 141.2) (C-5″, C-8″),
142.2 (triazole Cq), 139.6 (C-5), 134.6 (maleimide CH), 129.3
(C-6″), 129.1 (C-1‴), 126.8 (C-3″), 124.2 (C-7″), 123.3
(triazole CH), 122.1 (C-6), 116.4 (C-4″), 112.7 (C-2‴), 109.8
(C-1‴a), 102.3 (C-4‴), 83.3 (C-9‴), 73.2 (C-3), [69.72, 69.69,
69.64, 69.58, 69.1, 68.9] (C-33, C-34, C-35, C-36, C-37, C-38),
56.7 (C-α), 56.1 (C-14), 55.6 (C-17), 49.5 (C-9), 49.3 (C-39),
41.9 (C-13), 39.0 (2C, C-12, C-24), 38.6 (C-32), 37.7 (C-4),
37.0 (2C, C-1′, C-2′), 36.5 (C-1), 36.1 (C-10), 35.7 (C-22),
35.2 (C-20), 31.4 (C-8), 31.3 (C-7), [29.9, 29.3] (C-29, C-30),
28.3 (C-β), 27.8 (C-16), 27.4 (C-25), 27.3 (C-2), 23.9 (C-15),
23.2 (C-23), [22.7, 22.4] (C-26, C-27), 20.6 (C-11), 19.0 (C-
19), 18.6 (C-21), 11.7 (C-18); MS(MALDI) calcd for
C71H90N8O14S 1310.63, found 1311.63 [M+H]
+; ATR FT-IR
3600−2400 br, 3275, 3066, 2936, 2904, 2868, 1709, 1659,
1639, 1587, 1502, 1464, 1406, 1381, 1329, 1254, 1207, 1175,
1107, 1028, 993, 914, 850, 826, 696, 671 cm−1.
Expression and Puriﬁcation of mCherry Extended
with a C-terminal Cys (mCherry-Cys). Cys extended
mCherry with a His6 tag (Figure S6) was cloned into a
modiﬁed pRSET vector (Invitrogen). Transformed cells of E.
coli BL21(DE3) were grown at 37 °C in 1 L of LB medium
containing 100 μg/mL ampicillin. When OD600 = 0.6 was
achieved, the protein expression was induced by isopropyl-1-
thio-β-D-galactopyranoside in a ﬁnal concentration of 0.5 mM.
Cells were grown for further 4 h at 37 °C, and then harvested
by centrifugation at 5000 rpm for 15 min at 4 °C. The pellet
was resuspended in 40 mL of 50 mM Na2HPO4, 300 mM
NaCl, 10 mM imidazole, pH 8.0 containing a protease inhibitor
cocktail of Sigma, and cells were disrupted by sonication at 4
°C. The lysate was centrifuged at 15000 rpm for 30 min and the
supernatant was applied to a Ni-NTA column equilibrated with
the same buﬀer. The column was washed with 5 column
volumes of 50 mM Na2HPO4, 300 mM NaCl, 20 mM
imidazole, pH 8.0, and then the mCherry was eluted with 50
mM Na2HPO4, 300 mM NaCl, 250 mM imidazole, pH 8.0.
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Fractions containing the target protein were desalted on
Sephadex G-25 columns with Milli-Q water and stored at −20
°C as a frozen solution.
Conjugation of the Cholesterol Anchor to mCherry-
Cys. The protein conjugation of the cholesterol anchor was
investigated by the addition of diﬀerent molar excess of 8 to the
solution of mCherry (1 mg/mL, 36 μM) in 20 mM Tris, 10
mM TCEP, pH 7.5, and it was incubated at 20 °C for 1 h.
Then, 100 μL of the reaction mixture was introduced to a
Superdex 75 column and eluted with 50 mM Na2HPO4, 150
mM NaCl, pH 7.0 (Figure S4). On preparative scale, a
protein:anchor ratio of 1:10 was applied, and the total amount
of 8 was added in 10 portions over 5 h. The mixed micelles
composed of the cholesteryl lipoprotein and the cholesterol
anchor was puriﬁed by size-exclusion chromatography on
Superdex 75, and then the mixed micellar associates were
incubated with 10 equiv β-cyclodextrin at 20 °C for 24 h. The
inclusion complex of 8 and that of the protein−anchor
conjugate was separated with size-exclusion chromatography.
ECD Spectroscopy. ECD spectra of mCherry-Cys and the
mCherry−anchor conjugate in the 190−250 nm region were
recorded on a Jasco (Tokyo, Japan) J815 spectropolarimeter,
equipped with a Peltier temperature controller, at 25 °C and
100 nm/s scan speed using a 1 mm path length quartz cell.
Protein concentration of the samples was in the 2.5−6.5 μM
range as measured by the Bradford method.57 Spectra
presented here are accumulations of 10 scans and the
corresponding solvent spectra recorded under the same
conditions were subtracted. The contribution of each secondary
structural element of the protein was determined by
deconvolution of the spectra using the CDSSTR method.58
Cell Culture. For in vitro biological studies, SH-SY5Y
(ATCC: CRL-2266) human neuroblastoma cells were used.
They were cultured in DMEM (Sigma Ltd., St. Louis, MO,
USA) medium containing 10% FCS, L-glutamine (2 mM),
gentamycin (160 μg/mL), 1 mM pyruvate, and nonessential
amino acids (Sigma Ltd., St. Louis, MO, USA). The cultures of
cells were maintained at 37 °C in a humidiﬁed atmosphere with
5% CO2.
In Vitro Cytotoxic Eﬀect of the Cholesterol Anchor
and the mCherry−Anchor Conjugate. The in vitro
cytotoxic eﬀect of 8 and the mCherry−anchor 8 conjugate
was evaluated by the MTT-assay.59 For the experiment, 5 × 103
cells per well were plated on 96-well plates. After 24 h
incubation at 37 °C, cells were treated with 8 or with
mCherry−anchor 8 dissolved in serum-free medium (0.26 nM
− 100 μM and 0.26 nM − 10 μM, respectively) for 60 min.
The control cells were treated with serum-free medium for 60
min. MTT solution was added to the cells at a ﬁnal
concentration of 367 μg/mL; after 3.5 h incubation they
were centrifuged for 5 min at 863 × g and the supernatant was
removed. The formazan crystals were dissolved in DMSO and
the absorbance (A) of the samples was measured at λ = 540 and
620 nm using an ELISA Reader (Labsystems MS reader,
Finland). A620 was subtracted from A540 and the percent of
cytotoxicity was calculated using the following equation:
= − ×A ACytotoxicity (%) [1 ( / )] 100treated control
where Atreated and Acontrol correspond to the absorbance of the
treated and control cells, respectively.
Live Cell Imaging with Confocal Laser Scanning
Microscopy. 20 000 cells per well were plated on an 8-well
Lab-Tek II Chambered coverglass. After 48 h incubation at 37
°C, cells were treated with 3, 8, or mCherry−anchor 8
dissolved in serum-free medium for 30 min. The concentration
of the cholesterol probe and the cholesterol anchor was 1 μM,
while the mCherry−anchor 8 conjugate was applied at 10 μM
concentration. Cells treated with serum-free medium for 30
min were used as a negative control. After treatment and
incubation, cells were washed with serum-free medium and the
nuclei of the cells were stained for 5 min using the nuclear dye
DRAQ5. Sequential excitation was applied for ﬂuorescein,
mCherry, and DRAQ5. Fluorescein was excited with an Ar ion
laser (488 nm) and emitted photons were collected through a
BA 505−525 nm ﬁlter; mCherry was excited with a He−Ne
laser at 543 nm and emitted photons were collected through a
BA 595−615 nm ﬁlter; DRAQ5 was excited with a He−Ne
laser at 633 nm and emitted photons were collected through a
BA 660 nm ﬁlter. The colocalization of mCherry and
ﬂuorescein signals was quantitated on 15 confocal microscopy
images with more than 600 cells. In our case the intensities of
the two ﬂuorescent signals were diﬀerent (Figure 7, emission
spectra); therefore, Manders colocalization coeﬃcients were
calculated, which are not as aﬀected by diﬀerences in intensities
between the channels as the Pearson coeﬃcient. After
deconvolution and background subtraction, Manders coeﬃ-
cients were calculated using the JACoP plugin of ImageJ
software.60 Manders coeﬃcient varies between 0 and 1, where
M = 0 represents the lack of colocalization, while complete
colocalization is denoted by M = 1.61,62 Manders colocalization
coeﬃcient has two components: M1 and M2. M1 is deﬁned as
the ratio of the ‘summed intensities of pixels from the green
image for which the intensity in the red channel is above zero’
to the ‘total intensity in the green channel’ and M2 is deﬁned
conversely for the red channel.63
■ RESULTS AND DISCUSSION
Synthesis of the Cholesterol Probe and the Choles-
terol Anchor. Our semisynthetic strategy for the preparation
of cholesteryl lipoproteins is based on the Michael addition of a
C-terminally Cys extended recombinant protein to a maleimide
functionalized anchor. Cholesterol was chosen as the lipid
moiety of the anchor, because it presumably directs the
membrane anchored protein to cholesterol-rich membrane
microdomains where GPI-APs are also accumulated. The
headgroup of the anchor molecule was designed to be similar in
length to the glycan part of the GPIs, and to be able to expose
the attached protein to the extracellular space with a distance of
ca. 20 Å from the surface of the membrane bilayer (Figure S1).
A di(ethylene glycol) spacer between the cholesterol hemi-
succinate moiety and the trifunctional linker glycine derivative
provides hydrogen bond acceptor ether oxygens that improve
the hydrophilic character of the headgoup. Furthermore, the
conformational ﬂexibility of this type of spacer is expected to be
highly similar to that of the GPI glycan core. It is of interest to
note that an endocytosis-inhibiting eﬀect has been reported for
cholesteryl ethers with long PEG50 and PEG200 chains.
64 The
cholesterol moiety is attached via an ester bond to the
headgroup of the anchor. The hydrolytic stability of this
cholesteryl ester is crucial for the imaging applications where
the membrane anchored protein is to be visualized by the
ﬂuorescence of the headgroup of the anchor. In order to
investigate the hydrolytic stability and the membrane
association properties of the designed cholesterol anchor, the
model compound 3 was synthesized and subjected to
preliminary experiments. The cholesterol probe 3 was prepared
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from cholesteryl hemisuccinate. It was activated with TBTU in
the presence of DIEA, and used for the N-acylation of the
monotrityl protected 1,13-diamino-4,7,10-trioxa-tridecane
(Scheme 1). The application of HOBt and DIC resulted in
lower yield, and using a dichloromethane/chloroform mixture
was also required to achieve a yield of 95% in this acylation
step. The trityl group was chosen for protecting the terminal
amine, because it is cleaved by mild acids under a condition
where the cholesteryl ester is stable. The acidolytic removal of
the trityl group of 1 was performed in the presence of
triethylsilane that prevented the realkylation of the amine 2
during the deprotection. Finally, the addition of the amine 2 to
ﬂuorescein isothiocyanate resulted in the cholesterol probe 3.
The hydrolytic stability of the cholesteryl ester in 3 was
explored by incubating the probe in PBS at ambient
temperature, and HPLC analyses were performed at regular
time points. It was found that the HPLC peak area of the probe
remained constant over a period of 24 h (Figure 1), meaning
that the cholesteryl ester was not hydrolyzed. The chemical
stability of the cholesteryl ester is a prerequisite to imaging
applications, but the cholesteryl ester also needs to be resistant
against cellular esterases. In a subsequent experiment SH-SY5Y
cells were treated with 1 μM of 3, and an intensive membrane
staining was observed (Figure 2). These experiments suggested
that this cholesteryl ester was stable at physiological pH, and
that the hydrophilic headgroup did not prohibit the membrane
insertion of the cholesterol amphiphile.
The synthesis of the GPI mimetic cholesterol anchor was
conducted in a convergent way (Scheme 2). The synthetic
strategy is based on the [3 + 2] cycloaddition of a pegylated
azidocholesterol and an alkyne derivative; the latter contains
both a thiol reactive maleimide and a ﬂuorescent reporter. The
azide−alkyne cycloaddition is fairly fast and chemoselective,
and it tolerates the presence of numerous functional groups and
a wide range of solvents. Therefore, the demonstrated synthetic
strategy can be generally applied for the introduction of diverse
ﬂuorescent reporters and protein capture functional groups via
the alkyne component, i.e., the headgroup of the cholesterol
anchor can be ﬁne-tuned to the experimental setup. The size
and the hydrophilic character of the headgroup can be further
varied by the introduction of oligo(ethylene glycols) with
diﬀerent length into the azidocholesterol component. The
alkyne component was synthesized from propargylglycine
(Pra), because the Michael acceptor maleimide and the
ﬂuorescent reporter can be orthogonally coupled to the
carboxylic and amino groups of Pra without interfering with
the alkyne function. The protected maleimido Pra derivative 4
was prepared by the N-acylation of N-(2-aminoethyl)maleimide
with Boc-Pra-OH in the presence of HOBt, DIC, and DIEA.
The acidolytic removal of the Nα-Boc amino protecting group
of 4 resulted in the amine 5, and the ﬂuorescent alkyne 6 was
obtained by the addition of ﬂuorescein isothiocyanate. The
alkyne 6 was formed in high yield when 5 was liberated in situ
from the TFA salt during the isothiocyanate addition. The azide
Scheme 1. Synthesis of the Fluorescent Cholesterol Probea
a(a) 1 equiv TBTU, 1.3 equiv DIEA, CHCl3/CH2Cl2 (4:1), RT, 8 h, 95%; (b) TFA, TIS, CH2Cl2, RT, 5 × 10 min, 94%; (c) 1.2 equiv FITC, 1 equiv
DIEA, DMF, RT, 6 h, 47%.
Figure 1. Hydrolytic stability of the cholesterol probe 3. The peak area
of 3 in the incubated sample is indicated as a fraction of the peak area
of 3 in the starting solution. Representative chromatograms are shown
in Table S2.
Figure 2. Association of the cholesterol probe 3 (A) and the
cholesterol anchor 8 (B) with SH-SY5Y cell membranes. Cells were
treated with the compounds at a concentration of 1 μM for 30 min,
and nuclear staining was carried out with the nuclear dye DRAQ5 for 5
min. On the image, ﬂuorescein is green and nuclei are blue.
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component 7 was prepared by the N-acylation of 1-amino-11-
azido-3,6,9-trioxaundecane with cholesteryl hemisuccinate in
the presence of TBTU and DIEA. In the ﬁnal step the alkyne 6
was linked to the azidolipid 7 by 1,3-dipolar cycloaddition in
the presence of CuSO4 and sodium ascorbate in tBuOH/H2O
(1:1). The solubility of the resulting cholesterol anchor 8 was
investigated in aqueous medium before the protein conjugation
and the imaging application. The solution of 8 in serum free
medium was incubated at ambient temperature for 16 h, and
precipitation was not observed. Then SH-SY5Y cells were
treated with 1 μM of 8, and an intensive membrane staining
was obtained (Figure 2). Signiﬁcant loss of the membrane
ﬂuorescence was not observed even 1−3 h after the treatment
with 8, suggesting that the enzymatic cleavage of the headgroup
is negligible under our experimental conditions. Beyond an
eﬃcient cell membrane association, the lack of cytotoxicity is
also an important issue in live cell applications. Therefore the in
vitro cytotoxic eﬀect of the anchor was also investigated in a
subsequent MTT-assay. It was found that the ﬂuorescent
cholesterol anchor did not exhibit apparent cytotoxicity after 1
h treatment in the concentration range of 0.26 nM − 100 μM.
Molecular Dynamics Simulations. The atomic details of
the association of the cholesterol anchor 8 with DOPC
membrane was investigated by MD simulations. This
membrane model is a simpliﬁed representation of the cell
membrane that contains a vast variety of lipids and ca. 30%
proteins. However, it represents an electrostatic environment
similar to that of the biological membranes, and it is suitable for
studying the association mechanism and the atomic orientation
of the inserted anchor molecule. First, the simulation system
was validated by comparing experimental and calculated
characteristic data of the model DOPC bilayer. Good
agreement was found between the experimental65−67 and the
calculated values of area per lipid headgroup, bilayer thickness,
lateral diﬀusion coeﬃcient, and deuterium order parameters
(Table S3, Figure S2), which conﬁrmed that the applied MD
simulation conditions preserved the integrity of the model
DOPC bilayer. Two initial setups were created for the
production MD: 8 was initially embedded in the DOPC
membrane or 8 was initially in the aqueous phase. In the ﬁrst
case, 8 stayed embedded during a 200 ns simulation without
visible lateral diﬀusion. This observation is in agreement with
that the time scale of lateral diﬀusion was reported to be in the
range of microseconds.68 The angle between the membrane
plane normal and the vector connecting the 3β-oxygen and C-
20 atoms of the cholesterol moiety was found to vary between
0° and 75°, and the distance between C-α and 3β-oxygen varied
between 8 Å and 19 Å indicating vigorous axial diﬀusion and
wobbling of the cholesterol moiety of the anchor (Figure 3). In
spite of these fast and constant, nanosecond time scale
movements, the anchor molecule acquired a relatively stable
conformation and arrangement. The conformational change of
8 took place after approximately 20 ns of simulation time and
resulted in a special twice-bent shape, which remained relatively
stable until the end of the simulation (Figure 4). In this
arrangement the di(ethylene glycol) linker lies parallel to the
membrane plane, the polar groups of this moiety are in close
contact with the lipid headgroups, the cholesterol scaﬀold is
Scheme 2. Synthetic Route to the Green Fluorescent Cholesterol anchor 8a
a(a) 1 equiv HOBt, 1 equiv DIC, 1 equiv DIEA, THF, RT, 8 h, 90%; (b) TFA/CH2Cl2 (1:1), RT, 30 min, 96%; (c) 1.05 equiv FITC, 1.05 equiv
DIEA, THF, RT, 13 h, 69%; (d) 1.3 equiv TBTU, 1.3 equiv DIEA, CHCl3/CH2Cl2 (4:1), RT, 8 h, 90%; (e) 0.6 equiv NaAsc, 0.3 equiv CuSO4·
5H2O, tBuOH/H2O (1:1), RT, 48 h, 66%.
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immersed in the lipophilic region of the bilayer, and both the
maleimido and the ﬂuorescent reporter moieties of the
headgroup ﬂoat in the aqueous phase or form interactions
with the DOPC headgroups.
In the second simulation 8 was initially placed in the aqueous
phase, and association of the anchor molecule with the
membrane surface was observed (Figure S3). While ﬂoating
in the aqueous phase, 8 adopted a doubled up bent structure, in
which the aromatic rings of ﬂuorescein are packed against the
cholesterol scaﬀold to minimize the solvent accessible hydro-
phobic surface. Membrane association was initiated by polar
interactions between the exposed di(ethylene glycol) linker of 8
and the lipid headgroups, observed shortly after 100 ns of
simulation time. This initial association then led to the break-up
of the intramolecular hydrophobic interactions of 8 and
subsequently to the gradual immersion of the cholesterol
moiety into the DOPC leaﬂet. Although this anchor−
membrane complex remained stable for the rest of the
simulation time, formation of the twice-bent conformation of
8 identiﬁed in the ﬁrst MD simulation was not observed here. It
suggests that the spontaneous membrane association and
complete membrane embedding of 8 would take longer than
200 ns. It has to be mentioned that simulations presented here
were performed for an isolated cholesterol anchor molecule,
while 8 forms either micelles or β-cyclodextrin inclusion
complexes under the experimental conditions. Therefore, the
molecular mechanism of membrane embedding may be
diﬀerent from that described above. Nevertheless, the results
of the MD simulations are consistent with the experimental
observations of the stable and spontaneous membrane
Figure 3. Fluctuation of (A) the angle between the membrane plane normal and the vector connecting the 3β-oxygen and C-20 atoms of the
cholesterol moiety (red arrow), and (B) the distance between C-α and 3β-oxygen of anchor 8 (black arrow) during MD simulations.
Figure 4. Structure of the cholesterol anchor 8 embedded in DOPC model membrane; water and lipid molecules (A) or just water molecules (B) are
omitted for clarity.
Bioconjugate Chemistry Article
dx.doi.org/10.1021/bc4002135 | Bioconjugate Chem. 2013, 24, 1684−16971691
association of 8. Furthermore, atomic level information was
provided about the arrangement of the membrane−anchor
complex suggesting that, similarly to the GPI auxiliary, 8 could
expose the attached protein toward the aqueous phase while
ﬁrmly attaching it to the membrane surface.
Protein Conjugation of the Cholesterol Anchor. The
red ﬂuorescent protein mCherry lacking any native Cys
residues was chosen to optimize the protein−cholesterol
anchor conjugation, and to demonstrate that the designed
ﬂuorescent cholesterol derivative can anchor proteins to the cell
membrane. The C-terminal Cys extension of mCherry resulted
in a protein that possessed a single Michael donor thiol group
assuring the chemoselective addition of the anchor 8 to the
protein C-terminus. A further advantage of this two-color
ﬂuorescent lipoprotein conjugate (mCherry − red, ﬂuorescein
− green) is that its integrity, i.e., the equimolarity of the protein
and the anchor, can easily be assessed by SDS-PAGE and by
measuring the intensity of the ﬂuorescence emissions.
mCherry was overexpressed in E. coli with a His6 tag
preceding the C-terminal Cys residue, and it was puriﬁed from
the soluble fraction of the E. coli lysate by Ni-aﬃnity
chromatography. The conjugation of the cholesterol anchor 8
to mCherry-Cys was performed in 20 mM Tris, 10 mM TCEP
at pH 7.5. Under these conditions the β-barrel structure of the
protein remains intact, and the amphiphilic cholesterol anchor
forms highly stable micellar associates with an approximate
critical micellar concentration of 10−100 nM as estimated from
data on similar amphiphiles.55 It was found that the total
conversion of mCherry required 25-fold excess of anchor 8 in 1
h (Figure 5). This ratio suggests that the micelles of 8 compose
of ca. 25 cholesterol amphiphiles, and also that a micelle reacts
with a single protein molecule. On preparative scale a protein
to anchor ratio of 1:10 was applied, and the total amount of 8
was added in 10 portions over 5 h. After the Michael addition,
the mixed micelles of the cholesteryl mCherry conjugate and
the anchor 8 amphiphiles were separated from both the
unreacted protein and the anchor 8 micelles by gel
chromatography. According to the elution time, the micellar
associates of this cholesteryl mCherry preparation exhibited a
virtual molecular weight signiﬁcantly higher than that of the
mCherry (Figure S5). The gel chromatographic fraction
containing the mCherry−anchor 8 conjugate was subjected to
SDS-PAGE, and an intensive ﬂuorescence was detected in the
dye front indicating the presence of mixed micelles. These
mixed micellar associates keep the cholesteryl lipoprotein
dissolved in an aqueous medium. Nevertheless, it is essential to
remove the surplus ﬂuorescent cholesterol; otherwise, the
plasma membrane or the cholesterol homeostasis69 could be
perturbed during live cell imaging applications. Furthermore, if
the mixed micelles of the conjugate are used for the
introduction of the lipoprotein into the cell membrane, the
unambiguous imaging of the membrane anchored protein will
be impossible via the ﬂuorescence of the cholesterol anchor.
Puriﬁcation of the Cholesteryl Lipoprotein. Diﬀerent
methods were explored for the separation of the cholesteryl
lipoprotein from the surplus ﬂuorescent cholesterol anchor
with an emphasis on the retention of the native fold of the
protein. Dialysis is commonly used to remove small molecules
or lipid excess from protein samples; however, the stability of
the mixed micelles of 8 and cholesteryl mCherry limits the
performance of this technique. Extraction of the surplus
cholesterol anchor with polar solvents is another option, but
the application of chloroform denatured the protein. Refolding
of such a denatured cholesteryl lipoprotein was not feasible,
because the cholesterol residue permanently participates in
hydrophobic interactions, and thus, restricts the protein folding.
On the other hand, the application of detergents results in
mixed detergent micelles of the cholesteryl lipoprotein which
are free of surplus ﬂuorescent cholesterol anchors. The
introduction of the cholesteryl lipoprotein into the cell
membrane via such detergent micelles makes the imaging of
the membrane associated protein feasible, but the detergent
molecules have a membrane perturbing eﬀect that is to be
avoided. When the mixed micelles of mCherry−anchor 8 were
puriﬁed by reversed phase HPLC, the mixed micelles were
disrupted at an acetonitrile concentration of 50% and the
cholesteryl mCherry was eluted as a pure semisynthetic
product. However, the resulting lipoprotein lost the red
ﬂuorescent properties indicating the distortion of the β-barrel
structure of mCherry. Afterward, the refolding of this denatured
cholesteryl mCherry failed similarly to that of the chloroform
extracted cholesteryl mCherry. The application of an anchor
capture resin was also intended for the separation of the
lipoprotein and the anchor excess by ﬁltering oﬀ the resin
bound anchor. A cysteinyl CLEAR-amide resin was prepared
for that purpose, because it has beneﬁcial water swelling
properties. But the heterogeneous Michael addition was found
to be very slow, and the mixed micelles remained intact. Finally,
another approach was tried, where the cholesterol moiety of the
protein−anchor conjugate was sequestered by a reversible
complexation with β-cyclodextrin. It is based on the fact that β-
cyclodextrin forms a stable inclusion complex with cholester-
ol.70 In the presence of low concentration of β-cyclodextrin,
cholesterol can be incorporated into the plasma membrane
within a few minutes,71 because the exchange rate of cholesterol
between β-cyclodextrin and membranes is high. Furthermore,
β-cyclodextrin does not accelerate the extraction of phospho-
lipids from the cell membrane when the concentration of β-
cyclodextrin is below 20 mM.72 When the mixed micelles
composed of the cholesteryl mCherry and anchor 8 were
incubated with 10 equiv β-cyclodextrin, the micellar associates
were disrupted without any sign of denaturing the protein
(Figure 6). The hydrophobic cavity of the β-cyclodextrin binds
the cholesterol moiety of the conjugate and that of the surplus
anchor molecules forming host−guest complexes. The
molecular weight of the inclusion complex of the protein−
anchor 8 conjugate is signiﬁcantly higher than that of the
cholesterol anchor, and thus, their separation was achieved by
size-exclusion chromatography. The puriﬁed inclusion complex
Figure 5. Conjugation of the cholesterol anchor 8 with mCherry-Cys.
The concentration of the unreacted mCherry in the reaction mixture
after 1 h is indicated (◇).
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of the lipoprotein was subjected to SDS-PAGE analysis
followed by ﬂuorescence detection. The intensity of the
ﬂuorescent bands of the samples containing the mixed micelles
of cholesteryl mCherry and the β-cyclodextrin inclusion
complex of cholesteryl mCherry was measured, and the ratio
of the protein associated ﬂuorescence to the cholesterol anchor
ﬂuorescence was determined using the gel analyzing tool of
ImageJ software.60 The ratio of the intensity of the 27.6 kDa
band to the front was found to be 1:2.57 and 1:0.003 before
and after the puriﬁcation via the β-cyclodextrin inclusion
complex, respectively (Table S4). Thus, the ﬂuorescence
detection revealed that the mCherry−anchor 8 preparation
was free of surplus ﬂuorescent anchor.
Characterization of the Cholesteryl Lipoprotein. The
ﬂuorescence spectra of the pure lipoprotein exhibited the
characteristics of both ﬂuorophores with shoulders on the
emission spectrum of ﬂuorescein and on the excitation
spectrum of mCherry (Figure 7). The emission spectrum of
the red ﬂuorophore was also recorded at an excitation
wavelength of 543 nm, because it was applied during the
confocal laser scanning microscopic experiments. The red
ﬂuorescence of the β-cyclodextrin inclusion complex of
cholesteryl mCherry was indicative of the retention of the
native protein fold, but it was further evidenced by ECD
spectroscopy. Figure 8 shows the ECD spectra of mCherry−
Cys and those of the mCherry−anchor 8 conjugate. The
fractions of the secondary structural elements of the proteins
were calculated by deconvoluting these ECD spectra (Table 1).
An almost identical distribution of the helix, β-sheet, turn, and
random structures was found for the conjugate and the parent
mCherry−Cys. It indicates that the attachment of the
cholesterol anchor does not cause signiﬁcant change in the
protein structure, and that the β-barrel fold of mCherry is intact
both in the mixed micellar form and in the β-cyclodextrin
inclusion complex. The distribution of the secondary structural
elements was also calculated from the X-ray diﬀraction
structure of mCherry for comparison. The crystal structure
was analyzed with both the DSSP73 and STRIDE74 secondary
structure recognition algorithms, which yielded very similar
results. However, in the solution structures of mCherry−Cys
and the mCherry−anchor 8 conjugate, slightly higher fractions
of random structures and lower fractions of β-strands were
found. It could be attributed to the ﬂexible N- and C-terminal
regions of mCherry that are missing from the X-ray crystal
structure.
Imaging of the Cholesteryl Lipoprotein with Confocal
Laser Scanning Microscopy. It was shown that our approach
oﬀers an eﬀective way to prepare ﬂuorescent cholesteryl
lipoproteins without denaturing the protein fold. The integrity
of the resulting ﬂuorescent cholesteryl lipoprotein provides the
Figure 6. (A) Preparation of the lipid excess-free cholesteryl mCherry. The schematic green heads represent the green ﬂuorophore of the cholesterol
anchor 8; β-cyclodextrin is symbolized with a blue truncated cone; SEP.1. and SEP.2. indicate gel chromatographic separations. (B) Coomassie blue-
stained (left) and ﬂuorescence detected (right) 15% SDS-PAGE gel: lane 1, molecular weight marker; lane 2, mCherry (see Scheme S1 for the
hydrolysis of the red ﬂuorophore resulting in the multiple band pattern); lane 3, mixed micelles of cholesteryl mCherry (the cholesteryl derivatives of
the full length mCherry and the C-terminal mCherry fragment, and the surplus 8 are ﬂuorescent); lane 4, β-cyclodextrin inclusion complex of
cholesteryl mCherry (in order to emphasize the lack of surplus anchor 8, a larger amount of lipoprotein was introduced than in lane 3); lane 5,
cholesterol anchor 8. Quantitation of the ﬂuorescent signals on lanes 3 and 4 was carried out and the ratio of the protein associated ﬂuorescence to
the ﬂuorescence of the residual cholesterol anchor is given in Table S4.
Figure 7. (A) Excitation () and emission (- - -) spectra of the
cholesterol anchor 8 (50 μM in H2O) at 25 °C; λem = 525 nm and λex
= 488 nm. (B) Excitation (green, λem = 518 nm; red, λem = 610
nm) and emission (green - - -, λex= 488 nm; red - - -, λex= 543 and 587
nm) spectra of cholesteryl mCherry (20 μM in H2O) at 25 °C.
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advantage of avoiding the coadministration of surplus, non-
conjugated ﬂuorescent lipids and detergents, and thus, the
membrane perturbation by external lipid excess or detergents
can be excluded in live cell imaging applications. Importantly,
the ﬂuorescence signal of the anchor molecule can be
unambiguously assigned to the conjugated protein. In order
to introduce the semisynthetic lipoprotein into the plasma
membrane of live cells, the mCherry−anchor 8 conjugate was
added to a mammalian cell culture along with controls (anchor
8 or mCherry−Cys alone) and monitored by confocal laser
scanning microscopy. Images of SH-SY5Y cells incubated with
the β-cyclodextrin inclusion complex of the semisynthetic
mCherry−anchor 8 conjugate show green and red ﬂuorescence
on the cell membrane (Figure 9). This suggests that the protein
is successfully anchored to the cell membrane after exogenous
addition, and also that the protein structure is not aﬀected by
the membrane association. Red ﬂuorescence was not observed
when cells were treated with mCherry−Cys, conﬁrming that
the cholesteryl lipoprotein was ﬁrmly associated to the cell
membrane via the cholesterol anchor. The membrane
association of the conjugate also results in the liberation of β-
cyclodextrin from the inclusion complex. However, the
presence of 10−20 μM β-cyclodextrin in the cell culture
medium has no eﬀect on the normal cellular cholesterol level,
because the cholesterol extraction from the cell membrane
requires higher β-cyclodextrin concentration in the mM
range.75 It is important to note that, due to the structure of
the anchor and the moderate hydrophobicity of ﬂuorescein, the
ﬂuorescent reporter is expected to be situated extracellularly. It
is in agreement with the results of the MD simulations on the
anchor 8, where only the cholesterol residue immersed into the
outer leaﬂet of the membrane bilayer. This spatial arrangement
of the conjugate helps to maintain lipid−lipid interactions
speciﬁc for cholesterol, and proposes lateral diﬀusion properties
similar to that of cholesterol. These membrane biophysical
properties would be altered if the sterane skeleton was modiﬁed
with a ﬂuorescent molecule.76 The colocalization of the
ﬂuorophores also evidenced that the cholesteryl ester and
consequently the whole conjugate was stable under the
circumstances of the live cell imaging. In order to quantitate
the colocalization of the mCherry and ﬂuorescein ﬂuorophores,
the Manders colocalization coeﬃcients were calculated. The
original M1 and M2 values were found to be 0.993 ± 0.020 and
0.999 ± 0.001, respectively. These data represent high
colocalization, which is unambiguously visualized in Figure
9B. It is also visible on the diﬀerential interference contrast
picture that the conjugate exhibited no apparent toxic eﬀects on
the SH-SY5Y cells. This ﬁnding is in agreement with the results
Figure 8. ECD spectra of mCherry-Cys (red), mixed micelles of
cholesteryl mCherry (blue), and the β-cyclodextrin inclusion complex
of cholesteryl mCherry (green).
Table 1. Fractions of Secondary Structure Elements in
mCherry
protein helix
β-
sheet turns random
mCherrya 0.06 0.57 0.16 0.14
mCherryb 0.05 0.58 0.27 0.11
mCherry−Cysc 0.09 0.40 0.24 0.27
mCherry−anchor 8 conjugatec 0.05 0.43 0.24 0.28
mCherry−anchor 8 conjugate with β-
CDc
0.07 0.41 0.25 0.26
aResults obtained from PDB 2H5Q by DSSP algorithm. bResults
obtained from PDB 2H5Q by STRIDE algorithm. cResults obtained
from experimental ECD spectra by deconvolution.
Figure 9. Confocal laser scanning and diﬀerential interference contrast (right bottom) microscopy of SH-SY5Y cells after 30 min incubation (A)
with 1 μM cholesterol anchor 8, and (B) with β-cyclodextrin inclusion complex of 1 μM cholesteryl mCherry at 37 °C. On the images ﬂuorescein is
green, mCherry is red, and nuclei are blue. On the overlaid image (A and B, left bottom) yellow represents the colocalization of the ﬂuorescein and
mCherry signals.
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of the MTT assays, where the mCherry−anchor 8 conjugate
was found to be nontoxic at a concentration of 10 μM.
■ CONCLUSIONS
A general approach for the modiﬁcation of proteins with
ﬂuorescent cholesterol derivatives is suggested, where the
resulting semisynthetic proteins enable the direct imaging of
membrane associated cholesteryl proteins after exogenous
introduction into live cells. The appropriate cholesterol anchor
is prepared with a convergent synthetic strategy that allows
ﬂexibility in the molecular design of the headgroup, i.e., the
Michael acceptor, the length of the PEG spacer, and the
ﬂuorescent reporter molecule all can be ﬁne-tuned to the
preferences of the particular application, to the target protein,
and to the instrumentation. The stable membrane association
of the cholesterol anchor was conﬁrmed experimentally, and an
extracellular orientation of the headgroup is in agreement with
the molecular dynamics simulations performed with anchor 8.
As a proof of concept, the method was demonstrated on the
red ﬂuorescent protein mCherry that was conjugated with a
green ﬂuorescent anchor. Due to the presence and position of
the green ﬂuorescent reporter, the purity and the homogeneity
of the cholesteryl lipoprotein could be unambiguously analyzed.
Furthermore, the retention of the red ﬂuorescence of mCherry
was indicative of the preservation of the native protein fold after
cholesterol conjugation, and after delivery into membranes of
live cells. In imaging applications, the model protein mCherry
can be substituted with other target proteins having a C-
terminal Cys residue. The main advantage of our method is that
the use of the β-cyclodextrin inclusion complex of the protein
conjugate allows the treatment of live cells with ﬂuorescent
cholesteryl lipoproteins without the use of membrane
perturbing detergents. Furthermore, no surplus ﬂuorescent
lipids over the stoichiometric cholesterol moiety of the
semisynthetic lipoprotein are introduced into the cell
membrane. As a consequence, direct imaging of a membrane
anchored protein became feasible with a small molecule
ﬂuorophore, and thus, the strategy oﬀers a beneﬁcial alternative
to GFP fusions for studying membrane associated proteins. Our
conjugation method might also be applied in ﬂuorescence
microscopic investigation of the cellular traﬃc of GPI-APs and
in cell surface engineering, because the exogenous insertion of
pure cholesteryl lipoproteins into cell membranes causes a
lower degree of stress to the recipient cells as compared to the
liposome fusion or micelle fusion methods.
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lipid-modiﬁed proteins have important biological functions. A class of cell surface proteins contains a complex
glycosylphosphatidylinositol (GPI) glycolipid at the C-terminus, and they are accumulated in cholesterol-rich membrane
microdomains, that is, lipid rafts. Semisynthetic lipoproteins prepared from recombinant proteins and designed lipids are
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via reduction of the structural complexity. A synthetic headgroup was added to the 3β-hydroxyl group of cholesterol, an
essential lipid component of rafts, and the resulting cholesterol derivative was used as a simpliﬁed GPI mimetic. In order
to quantitate the membrane integrated GPI mimetic after the exogenous addition to live cells, a tritium labelled cholesterol
anchor was prepared. The radioactive label was introduced into the headgroup, and the radiolabelled GPI mimetic anchor
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A unique class of cell membrane-associated proteins contains a
C-terminal glycosylphosphatidylinositol (GPI) moiety, and these
lipoproteins associate with the outer leaﬂet of the membrane
bilayer via the lipid chains of the GPI molecule. GPI-anchored
proteins are functionally diverse including enzymes, cell
adhesion molecules, receptors, complement regulatory
proteins, immunoproteins and further proteins (e.g. prion
protein) with unknown functions.1 It was shown that their
biological functions were retained after exogenous addition to
membranes2–5; therefore, semisynthetic lipoproteins
containing diverse reporters in the headgroup of the lipid
moiety can be valuable probes for investigating GPI-anchored
proteins.6–13 The GPI moiety directs the attached protein
towards the extracellular space and locates the attached
protein in special membrane microdomains, that is, lipid rafts.
Because cholesterol maintains the dynamic lipid–lipoprotein
associates of GPI-anchored proteins, sphingolipids and
cholesterol,14,15 it is hypothesized that cholesteryl lipoproteins
may also be accumulated in lipid rafts.16 Based on the ﬁnding
that cholesteryl poly(ethylene glycol) ethers accumulate in
cholesterol-rich membranes and their cytotoxicity is low,17 we
have recently prepared a cholesterol derivative containing both
a maleimide and a ﬂuorescent reporter in the headgroup for
protein conjugation and imaging, respectively. It was shown
that after protein conjugation, the semisynthetic cholesteryl
lipoprotein could be puriﬁed via a β-cyclodextrin inclusion
complex that made the cholesterol moiety soluble in polar
solvents. Then, the lipid excess- and detergent-free lipoproteinJ. Label Compd. Radiopharm 2015, 58 7–13could be introduced into the cell membrane of live cells with
minimal disruption of the membrane, and the ﬂuorescence of
the headgroup could be unambiguously assigned to the
attached protein.18 In order to further study the membrane-
associated cholesteryl lipoproteins, it is important to quantitate
the lipoprotein incorporated into the cell membrane. It can be
achieved by determining the radioactivity of cell membrane
preparations or intact cells treated with a tritium labelled
analogue of the anchor molecule. Herein, we report our results
on the preparation and biological application of a tritium
labelled cholesterol derivative designed for that purpose.Copyright © 2015 John Wiley & Sons, Ltd.
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8Experimental
The purity of all reagents and solvents was analytical or the highest
commercially available grade. Protected propargylglycine (Pra) and
5-amioﬂuorescein were purchased from Bachem Feinchemicalen AG
(Bubendorf, Switzerland), and coupling reagents and substituted di
(ethylene glycols) were obtained from Calbiochem-Novabiochem AG
(Läufelﬁngen, Switzerland). Other chemicals were from Sigma Ltd. (St.
Louis, MO, USA). Tritium labelling was carried out in a self-designed
vacuum manifold,19,20and radioactivity was measured with a Packard
Tri-Carb 2100 TR liquid scintillation analyser using Hionic-Fluor
scintillation cocktail of PerkinElmer (Waltham, MA, USA). Analytical thin
layer chromatography (TLC) was performed on 5 × 10 cm glass plates
precoated with silica gel 60 F254 (Merck, Darmstadt, Germany), spots
were visualized with UV light, ninhydrin or phosphomolybdic acid, and
radioactivity was detected with a Berthold LB511 linear TLC analyser.
Flash chromatography was carried out on silica gel 60 (Sigma Ltd., St.
Louis, MO, USA) using the indicated solvents. Analytical and
semipreparative HPLC separations were performed with a Merck-Hitachi
LaChrom system under the indicated conditions. Radio-HPLC was
performed on a Jasco HPLC system equipped with a Packard Radiomatic
505 TR Flow Scintillation Analyser. NMR spectra were recorded on a
Bruker Spectra DRX 500MHz spectrometer in the indicated solvent, and
chemical shifts (δ) are reported in ppm after calibration to the solvent
signals. Molecular weights of the compounds were determined by MS
analysis on a Finnigan TSQ 7000 spectrometer equipped with an ESI
source or on a Bruker reﬂex III MALDI-TOF spectrometer. In the case of
MALDI-MS, 2,5-dihydroxybenzoic acid matrix was applied. Mass
spectrometric measurements of [2H]piperidine were performed on a
Micromass Q-TOF Premier mass spectrometer (Waters MSTechnologies,
Manchester, UK) equipped with a nanoelectrospray ion source. The
instrument was scanned in the mass range of 85–90. Peak intensities were
calculated for [M+H]+, [M(2H1) + H]
+, [M(2H2) + H]
+ and [M(2H3) + H]
+
molecule ions by the Masslynx software. The measured peak intensities
of mono-, di- and tri-deuterated ions were corrected by the calculated
intensities of overlapping [M(13C) + H]+, [M(2H1,
13C) + H]+ and [M
(2H2,
13C) + H]+ peaks, respectively. The effects of [M(13C2) + H]
+ and [M
(2H1,
13C2) + H]
+ and 15N containing ions were neglected. Live cells
treated with the ﬂuorescent anchor were visualized with an Olympus
IX81 confocal laser scanning microscope, and images were prepared by
the FluoView 500 software.[2H]piperidine (1)
An amount of 5mg of 4-bromopiperidine hydrobromide (20 μmol) was
dissolved in 400 μL of 10M NaOH, and it was extracted with 1mL of
EtOAc. The organic phase was washed with brine, dried over Na2SO4
and evaporated at atmospheric pressure. The resulting amine was
dissolved in 500 μL of EtOAc, and it was reduced under 0.4 bar deuterium
gas in the presence of 11mg of Pd/C (10% Pd) catalyst. After 3 h, the
catalyst was ﬁltered off, and the EtOAc solution was extracted with 1M
HCl. [2H]piperidine hydrochloride (1) was obtained after repeated
evaporations from the acidic aqueous solution (2mg, 82%). Rf 0.38 (n-
BuOH–AcOH–H2O 2:1:1); ESI-MS calcd for C5H10DN 86.10, found 87.09
[M + H]+.[3H]piperidine
Tritium labelling was performed with 2.1mg of 4-bromopiperidine base
(12.9 μmol) dissolved in 1mL of EtOAc in the presence of 5mg of Pd/C
(10% Pd) catalyst. The reaction mixture was degassed prior to tritium
reduction by a freeze–thaw cycle, and then it was stirred under 0.4 bar
of tritium gas for 3 h, followed by the ﬁltration of the catalyst. The EtOAc
solution was extracted with 1M HCl, and labile tritium was removed by
repeated evaporations from 1M HCl solution. Finally, 20.5 GBq of [3H]
piperidine hydrochloride was isolated as a white solid (s.a. 1.58 TBq/
mmol), which was immediately used for the next step.www.jlcr.org Copyright © 2015 Joh[3H]N-nitrosopiperidine
The solid [3H]piperidine hydrochloride (20.5 GBq) was dissolved in 100 μL
of 1M HCl, and the solution was cooled into ice. Then, 250mg of KNO2
was added, and the reaction mixture was stirred at 0 °C for 2 h followed
by extraction with Et2O. The ethereal solution was evaporated at
atmospheric pressure yielding 17.8 GBq (87%) of crude [3H]N-
nitrosopiperidine. It was dissolved in 100 μL THF and immediately used
in the next step without further puriﬁcation. Rf 0.28 (petroleum
etheracetone 9:1), 93% radiochemical purity by radio-TLC.
[3H]N-aminopiperidine (2)
The solution of 17.8 GBq of [3H]N-nitrosopiperidine in 100 μL of THF was
transferred to a reaction vessel equipped with a condenser. A suspension
of 4.5mg of LiAlH4 in 600 μL of THF was added, and the reaction mixture
was stirred under Ar at 60 °C for 3.5 h. After cooling, 100 μL of 10M NaOH
was added, and it was stirred for further 20min. The resulting slurry was
extracted with Et2O, and the ethereal solution was extracted with 3M
HCl. The HCl solution was evaporated, and labile tritium was removed
by repeated evaporations from water : ethanol (1:1), resulting in 8.4 GBq
(47%) of solid [3H]N-aminopiperidine hydrochloride (0.8 mg), which was
used for the preparation of 8 without further puriﬁcation. Rf 0.38 (n-
BuOHAcOHH2O 2:1:1), 73% radiochemical purity by radio-TLC, s.a.
1.33 TBq/mmol.
Cholesteryl (S)-1-(4-(2-(tert-butoxycarbonylamino)-2-
carboxyethyl)-1H-1,2,3-triazol-1-yl)-13-oxo-3,6,9-trioxa-12-
azahexadecan-16-oate (3)
Boc-Pra-OH (60mg, 281.4μmol) was dissolved in 1mL of dimethylformamide
(DMF), and it was added to the solution of cholesteryl 1-azido-13-oxo-3,6,9-
trioxa-12-azahexadecan-16-oate18 (230mg, 335.0μmol) in CH2Cl2 (4mL).
Then, a solution of L(+)-ascorbic acid sodium salt (33.4mg, 168.8μmol) and
CuSO4.5H2O (21.1mg, 84.4μmol) in water (4mL) was added. The reaction
mixture was stirred for 8 h at room temperature, and then it was evaporated
in vacuo. The crude product was puriﬁed by column chromatography
(CHCl3MeOHAcOH 90:9:1) to give 230.4mg (91%) of pure 3 as a white
solid. Rf 0.30 (CHCl3MeOHAcOH 90:9.5:0.5); k′=8.61 (tR = 12.5min; Vydac
214TP5410 C4 column (100 × 4.6mm, 5 μm), gradient elution with 1.8%/min
acetonitrile (ACN) (0.08% (v/v) triﬂuoroacetic acid (TFA) in H2O (0.1%(v/v)
TFA) starting from 50% ACN, ﬂow rate: 1mL/min, λ = 216 nm); 1H NMR
(500MHz, CDCl3) δ 7.63 (s, 1H), 6.63 (s, 1H), 5.61 (s, 1H), 5.34 (d, 1H,
J= 3.7 Hz), 4.58 (s, 2H), 4.53 (m, 1H), 4.47 (s, 1H), 3.86 (s, 2H), 3.60 (m, 10H),
3.42 (q, 2H, J=4.6 Hz), 3.28 (m, 2H), 2.62 (t, 2H, J=6.7Hz), 2.47 (t, 2H,
J= 6.7 Hz), 2.29 (d, 2H, J= 7.6 Hz), 1.98 (m, 1H), 1.93 (m, 1H), 1.83 (m, 3H),
[1.62–1.00 (m, 18H): 1.57 (3H), 1.52 (1H), 1.48 (2H), 1.40 (1H), 1.32 (1H), 1.30
(2H), 1.20 (1H), 1.14 (1H), 1.11 (4H), 1.09 (2H)], 1.42 (s, 9H), 1.00 (s, 3H),
[0.99–0.86 (m, 3H): 0.94 (2H), 0.88 (1H)], 0.90 (d, 3H, J=6.4 Hz), [0.86 (d, 3H,
J= 1.8 Hz), 0.84 (d, 3H, J=1.8Hz)], 0.66 (s, 3H); 13C NMR (125MHz, CDCl3) δ
172.7, 172.1, 155.7, 142.7, 139.7, 124.1, 122.7, 80.0, 74.5, 70.7, 70.5, 70.3,
70.1, 69.9, 69.5, 56.8, 56.2, 53.3, 50.5, 50.1, 42.4, 39.8, 39.6, 39.3, 38.2, 37.1,
36.7, 36.3, 35.9, 32.0 (2C), 31.0, 30.0, 28.5, 28.3, 28.12, 28.07, 27.8, 24.4, 23.9,
22.9, 22.7, 21.1, 19.4, 18.8, 12.0; MS(MALDI) calcd for C49H81N5O10 899.60,
found 900.44 [M+H]+.
Cholesteryl (S)-1-(4-(2-amino-2-carboxyethyl)-1H-1,2,3-
triazol-1-yl)-13-oxo-3,6,9-trioxa-12-azahexadecan-16-oate
(4)
Compound 3 (200mg, 222.3 μmol) was dissolved in 2mL of TFACH2Cl2
1:1, and it was stirred for 30min. The solution was evaporated in vacuo to
give 197.0mg (97%) of pure 4 triﬂuoroacetate as a pale yellow solid. Rf
0.12 (CHCl3–MeOH–AcOH 90:9.5:0.5); k′ = 4.15 (tR = 6.7min; Vydac
214TP5410 C4 column (100 × 4.6mm, 5 μm), gradient elution with
1.8%/min ACN (0.08% (v/v) TFA) in H2O (0.1%(v/v) TFA) starting from
50% ACN, ﬂow rate: 1mL/min, λ = 216 nm); MS(MALDI) calcd for
C44H73N5O8 799.55, found 800.48 [M + H]
+.n Wiley & Sons, Ltd. J. Label Compd. Radiopharm 2015, 58 7–13
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9Cholesteryl (S)-1-(4-(2-carboxy-2-(3-(maleimido)
propanamido)ethyl)-1H-1,2,3-triazol-1-yl)-13-oxo-3,6,9-
trioxa-12-azahexadecan-16-oate (5)
The amino acid derivative 4 (140mg, 153.2μmol) and N-ethyldiisopropylamine
(DIEA) (61 μL, 350.4 μmol) were dissolved in MeOH (4 mL), and 3-
maleimidopropionic acid N-hydroxysuccinimide ester (56.0mg, 210.4μmol)
was added. Themixture was stirred for 3 h at room temperature, and then it
was evaporated in vacuo. The crude product was puriﬁed by column
chromatography (CHCl3–MeOH–AcOH 85:14:1) to give 118mg (81%) of
pure 5 as a white solid. Rf 0.43 (CHCl3–MeOH–AcOH 80:19:1); k′= 6.53
(tR = 9.8min; Vydac 214TP5410 C4 column (100 × 4.6mm, 5 μm), gradient
elution with 1.8%/min ACN (0.08% (v/v) TFA) in H2O (0.1%(v/v) TFA) starting
from 50%ACN, ﬂow rate: 1mL/min, λ = 216 nm); 1H NMR (500MHz, CDCl3) δ
7.70 (s, 1H), 7.02 (brs, 1H), 6.68 (s, 2H), 6.63 (brs, 1H), 5.34 (d, 1H, J= 3.7Hz),
4.77 (brs, 1H), 4.57 (m, 2H), 4.49 (s, 1H), 3.82 (m, 4H), 3.61 (m, 10H), 3.42 (q,
2H, J= 4.6Hz), 3.24 (m, 2H), 2.62 (t, 2H, J= 6.7 Hz), 2.58 (t, 2H, J= 6.3 Hz),
2.47 (t, 2H, J= 6.7Hz), 2.30 (d, 2H, J= 7.6Hz), 2.01 (m, 1H), 1.94 (m, 1H),
1.83 (m, 3H), [1.62–1.03 (m, 18H): 1.57 (3H), 1.52 (1H), 1.48 (2H), 1.40 (1H),
1.32 (1H), 1.30 (2H), 1.20 (1H), 1.14 (1H), 1.11 (4H), 1.09 (2H)], 1.00 (s, 3H),
[0.99–0.86 (m, 3H): 0.94 (2H), 0.88 (1H)], 0.90 (d, 3H, J= 6.4Hz), [0.86 (d, 3H,
J= 1.8 Hz), 0.84 (d, 3H, J= 1.8 Hz)], 0.66 (s, 3H); 13C NMR (125MHz, CDCl3) δ
172.80, 172.7, 172.2, 170.7, 169.9, 142.7, 139.8, 134.3, 124.3, 122.8, 74.5,
70.6, 70.5, 70.3, 70.0, 69.9, 69.4, 56.8, 56.3, 53.5, 50.5, 50.1, 42.4, 39.8, 39.6,
39.4, 38.2, 37.1, 36.7, 36.3, 35.9, 34.6, 34.3, 32.0 (2C), 31.0, 30.0, 28.4, 28.1
(2C), 27.9, 24.4, 24.0, 23.0, 22.7, 21.2, 19.4, 18.8, 12.0; MS(MALDI) calcd for
C51H78N6O11 950.57, found 951.45 [M+H]
+.
Fluorescent cholesterol anchor 6
The maleimide derivative 5 (50mg, 52.6μmol) and 1-[Bis(dimethylamino)
methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexaﬂuorophosphate
(HATU) (20.0mg, 52.6μmol) were dissolved in THF (5mL), and DIEA
(9.1μL, 52.6μmol) was added to the solution. It was stirred for 5min
followed by the addition of ﬂuorescein amine (54.8mg, 157.8μmol) in
THF (2mL). The reaction mixture was stirred for 16 h at room temperature,
and then it was evaporated in vacuo; the crude product was puriﬁed by
column chromatography (CHCl3–MeOH–AcOH 90:9:1) to give 37.0mg
(55%) of pure 6 as an orange solid. Rf 0.41 (CHCl3–MeOH–AcOH 90:9:1); k′
= 8.53 (tR = 12.4min; Vydac 214TP5410 C4 column (100 × 4.6mm, 5 μm),
gradient elution with 1.8%/min ACN (0.08% (v/v) TFA) in H2O (0.1%(v/v)
TFA) starting from 50% ACN, ﬂow rate: 1mL/min, λ = 216 nm); 1H NMR
(500MHz, (CD3)2SO) δ 10.30 (s, 1H), 10.21 (brs, 2H), 8.43 (s, 1H), 8.32 (d,
1H, J= 5.7 Hz), 7.89 (t, 1H, J= 5.4 Hz), 7.79 (s, 1H), 7.74 (d, 1H, J= 8.3 Hz),
7.15 (d, 1H, J= 8.3 Hz), 6.97 (s, 2H), 6.90 (s, 2H), 6.87 (dd, 2H, J= 8.6, 2.6 Hz),
6.73 (dd, 2H, J= 8.6, 1.6 Hz), 5.31 (d, 1H, J= 3.2 Hz), 5.09 (q, 1H, J= 5.8 Hz),
4.47 (t, 2H, J= 5.1 Hz), 4.42 (m, 1H), 3.92 (m, 2H), 3.77 (t, 2H, J= 5.1 Hz),
3.45 (brs, 10H), 3.38 (q, 2H, J= 5.7 Hz), 3.12 (m, 1H), 3.05 (dd, 1H, J= 14.9,
7.1 Hz), 2.71 (m, 2H), 2.43 (t, 2H, J= 6.7 Hz), 2.34 (t, 2H, J= 6.7 Hz), 2.22 (d,
2H, J = 7.6 Hz), 1.92 (m, 1H), 1.85 (m, 1H), 1.76 (m, 3H), [1.60–0.92
(m, 21H): 1.48 (2H), 1.52 (1H), 1.47 (1H), 1.44 (2H), 1.39 (1H), 1.28
(3H), 1.17 (1H), 1.13 (1H), 1.11 (4H), 1.02 (1H), 1.00 (1H), 0.97 (1H),
0.96 (1H), 0.91 (1H)], 0.95 (s, 3H), 0.87 (d, 3H, J = 6.4 Hz), 0.84 (d, 3H,
J = 2.0 Hz), 0.81 (d, 3H, J = 2.0 Hz), 0.65 (s, 3H, 18-H); 13C NMR
(125 MHz, (CD3)2SO) δ 171.5, 171.2, 171.0, 170.6, 169.3, 168.5, 159.2,
152.7, 146.5, 142.8, 142.1, 139.2, 134.1, 129.6, 125.9, 125.5, 125.3,
123.1, 121.9, 116.9, 114.0, 109.1, 101.3, 83.8, 72.8, 69.8, 69.7 (2C),
69.6, 69.3, 69.2, 56.1, 55.9, 55.4, 49.5, 49.4, 42.1, 39.1, 39.0, 38.8,
37.7, 36.6, 36.1, 35.7, 35.0, 34.9, 34.5, 31.8, 31.1, 29.7, 29.2, 27.9,
27.7, 27.4, 27.2, 23.9, 23.3, 22.6, 22.4, 20.9, 19.0, 18.6, 11.7; MS(MALDI)
calcd for C71H89N7O15 1279.64, found 1280.56 [M + H]
+.
Cholesterol anchor 7
The maleimide derivative 5 (25mg, 26.3 μmol), N-hydroxybenzotriazole
(HOBt) (3.6mg, 26.3 μmol) and N,N’-diisopropylcarbodiimide (DIC) (4 μL,
26.3 μmol) were dissolved in DMF (2mL). Then, N-aminopiperidine
(3.1 μL, 29 μmol) was added, and the solution was stirred for 16 h at roomCopyright © 2015 JohnJ. Label Compd. Radiopharm 2015, 58 7–13temperature. It was evaporated in vacuo, and the crude product was
puriﬁed by HPLC on a Discovery Bio Wide Pore C5 column to give
16mg (59%) of pure 7 as a white solid. Rf 0.45 (CHCl3–MeOH–TEA
90:9.9:0.1); k′ = 4.31 (tR = 6.9min; Vydac 214TP5410 C4 column
(100 × 4.6mm, 5 μm), gradient elution with 1.5%/min ACN (0.08% (v/v)
TFA) in H2O (0.1%(v/v) TFA) starting from 60% ACN, ﬂow rate:
1mL/min, λ = 216 nm); 1H NMR (500MHz, CDCl3) δ 7.63 (s, 1H), 7.08 (s,
1H), 6.68 (s, 2H), 6.60 (s, 1H), 6.48 (s, 1H), 5.34 (d, 1H, J = 3.7 Hz), 4.87
(brs, 1H), 4.55 (m, 2H), 4.46 (s, 1H), 3.83 (s, 4H), 3.61 (brs, 10H), 3.42 (q,
2H, J = 4.6 Hz), 3.20 (m, 2H), 2.73 (m, 4H), 2.62 (t, 2H, J = 6.7 Hz), 2.58 (t,
2H, J = 6.7 Hz), 2.47 (t, 2H, J = 7.6 Hz), 2.29 (d, 2H), 1.99 (m, 1H), 1.96 (m,
1H), 1.83 (m, 3H), 1.71 (m, 4H), [1.58–1.01 (m, 20H): 1.55 (3H), 1.50 (1H),
1.47 (2H), 1.43 (m, 3H), 1.32 (1H), 1.30 (2H), 1.23 (1H), 1.14 (1H), 1.11
(4H), 1.09 (1H), 1.05 (1H)], 1.00 (s, 3H), [0.96–0.83 (m, 3H): 0.96 (1H), 0.92
(1H), 0.90 (1H)], 0.88 (d, 3H, J = 6.4 Hz), [0.86 (d, 3H, J = 1.8 Hz), 0.84 (d,
3H, J = 1.8 Hz)], 0.66 (s, 3H); 13C NMR (125MHz, CDCl3) δ 172.7, 172.2,
170.7, 169.9, 156.8 142.7, 139.8, 134.3, 124.3, 122.8, 74.5, 70.6, 70.5, 70.3,
70.0, 69.9, 69.4, 63.4, 56.8, 56.3, 53.6, 50.5, 50.1, 42.4, 39.8, 39.6, 39.4,
38.2, 37.1, 36.7, 36.3, 35.9, 34.6, 34.3, 32.0 (2C), 31.0, 30.0, 28.4, 28.14,
28.12, 27.9, 27.2, 24.4, 24.0, 23.5, 23.0, 22.7, 21.2, 19.4, 18.8, 12.0; MS
(MALDI) calcd for C56H88N8O10 1032.66, found 1033.58 [M + H]
+.
[3H]cholesterol anchor 8
The maleimide derivative 5 (1 mg, 1 μmol) was dissolved in DMF (300 μL)
containing HOBt (0.13mg, 1 μmol), DIC (0.14 μL, 1 μmol) and DIEA
(0.09 μL, 0.5 μmol). Then, [3H]N-aminopiperidine (100MBq) dissolved in
24 μL of DMF was added, and the solution was stirred for 16 h at room
temperature. It was evaporated in vacuo; the crude product was
dissolved in HFIP, and it was puriﬁed by HPLC on a Vydac 214TP5410
column to give 17.4MBq of pure 8. k′ = 4.31 (tR = 6.9min; Vydac
214TP5410 C4 column (100 × 4.6mm, 5 μm), gradient elution with
1.5%/min ACN (0.08% (v/v) TFA) in H2O (0.1%(v/v) TFA) starting from
60% ACN, ﬂow rate: 1 mL/min, λ = 216 nm), s.a. 1.37 TBq/mmol.
Cell culture
SH-SY5Y (ATCC: CRL-2266) human neuroblastoma cells were used to test
the membrane association potency of 6 and 8. Cells were cultured in
DMEM (Sigma Ltd., St. Louis, MO, USA) medium containing 10% FCS,
L-glutamine (2mM), gentamycin (160 μg/mL), 1mM pyruvate and non-
essential amino acids (Sigma Ltd., St. Louis, MO, USA). The cell culture
was maintained at 37 °C in a humidiﬁed atmosphere with 5% CO2.
Live cell imaging with confocal laser scanning microscopy
Twenty thousand cells per well were plated on an 8-well Lab-Tek II
Chambered cover glass. After 48 h incubation at 37 °C, cells were treated
with 1 μM of 6 dissolved in serum-free medium containing 10 μM β-
cyclodextrin for 30min. Cells treated with serum-free medium for
30min were used as a negative control. After treatment and incubation,
cells were washed with serum-free medium, and the nuclei of the cells
were stained for 5min with DRAQ5. Sequential excitation was applied
for ﬂuorescein and DRAQ5. Fluorescein was excited with an Ar ion laser
(488 nm), and emitted photons were collected through a BA 505–525 nm
ﬁlter; DRAQ5 was excited with a He–Ne laser at 633 nm, and emitted
photons were collected through a BA 660 nm ﬁlter.
Membrane incorporation of [3H]cholesterol anchor 8
106 cells per well were plated on a 24-well plate, and after 12 h
incubation at 37 °C, cells were treated with 1–100 nM of 2 or 8 dissolved
in serum-free medium containing 10 μM β-cyclodextrin for 10 and 30min.
Then, cells were washed with serum-free medium and trypsinized. The
resulting cell suspensions were ﬁltered on a GF/B ﬁlter (Whatman) using a
24-well cell harvester (Brandel) and washedwith phosphate-buffered saline
(PBS) pH7.4. Filter discs containing the cells were immersed into Ultima
Gold XR scintillation cocktail, and they were counted in glass vials with awww.jlcr.orgWiley & Sons, Ltd.
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10Packard Tri-Carb 2100 TR LSA. Cells treated with serum-free medium for
30 min were used for background counting.
Results and discussion
Our earlier studies revealed that a maleimide functionalized
ﬂuorescent cholesterol derivative is capable of anchoring
proteins to the plasma membrane of live cells.18 The headgroup
of the anchor molecule contains a diethylene glycol residue,
which increases the polarity of the molecule and exposes the
attached protein towards the extracellular space. When applied
in a form of β-cyclodextrin inclusion complex, the headgroup
ﬂuorescence of the cholesterol anchor can be used for the
unambiguous visualization of the attached protein after cell
membrane delivery. In order to determine the membrane
concentration of the cholesterol anchor, a tritium labelled
analogue (8) was designed. By using this compound, the
quantitation of the membrane incorporated protein anchor can
be achieved by measuring the radioactivity of cell membrane
preparations or intact cells. For this purpose, a deﬁned position
of the radioactive label is crucial. Although [1,2-3H]cholesterol
complexed with β-cyclodextrin was reported to use for the fast
enrichment of cell membranes with labelled cholesterol,21 and
it was also used in studying the cyclodextrin-mediated
cholesterol transfer between different lipid layers22; cholesterol
labelling is not appropriate for our purposes. The headgroup of
the cholesterol anchor can be enzymatically removed via the
hydrolysis of the cholesteryl ester, and as a result the labelled
cholesterol, moiety remains in the cell membrane and the
unlabelled headgroup is released to the cell culture medium. In
this case, the membrane radioactivity is not affected by the
presence or lack of the headgroup, and the process cannot beScheme 1. Preparation of the ﬂuorescein and tritium labelled cholesterol anchors:
30 min; (c) 2 eq DIEA, MeOH, RT, 3 h; (d) HATU, DIEA, THF, RT, 16 h; (e) HOBt, DIC, DM
www.jlcr.org Copyright © 2015 Johdetected, resulting in overestimation of the amount of the
membrane-associated cholesterol anchor. In contrast, if the
tritium label is incorporated into the headgroup of the anchor
molecule, enzymatic removal of the headgroup will result in
decreasing radioactivity of the cell membrane preparation and
also emerging the labelled headgroup in the cell culture medium.
In order to introduce the radioactive label into the cholesterol
anchor headgroup, a convergent synthetic strategy was applied.
The tritium label was incorporated into a small molecule that was
coupled to an anchor fragment bearing both the cholesterol
residue and the bulk of the headgroup. The advantage of this
approach is that tritium incorporation either into the cholesterol
moiety or into other parts of the headgroup is excluded. The
cholesterol amphiphile 4 is an appropriate intermediate, because
primary amine and carboxylic acid functions in the headgroup
are available for the introduction of a radiolabelled or a
ﬂuorescent tag, and a protein conjugation function as well. It
was prepared from Nα-tBoc-protected propargylglycine and
cholesteryl 1-azido-13-oxo-3,6,9-trioxa-12-azahexadecan-16-oate
via a dipolar cycloaddition in the presence of CuSO4 and sodium
ascorbate (Scheme 1). The Nα-tBoc-protecting group was
removed by TFA in DCM, and the amine 4 was liberated in situ
with DIEA during the next step. Then, 4 was used for the
preparation of two constitutionally related tritium or ﬂuorescein
labelled anchors. First, the thiol reactive maleimide group was
coupled to the amine 4, because this way, the co-existence of a
Michael acceptor and a primary amine in an intermediate
compound is excluded that otherwise could lead to self-addition
under the basic conditions of the introduction of the labelling
tag. It was found that the amino function of 4 reacts faster with
an N-hydroxysuccinimide ester than with a maleimide, and
accordingly, the N-acylation of 4 with 3-maleimidopropionic acid(a) NaAsc, CuSO4.5H2O, DMF–CH2Cl2–H2O (1:4:4), RT, 8 h; (b) TFA–CH2Cl2 (1:1), RT,
F, RT, 16 h.
n Wiley & Sons, Ltd. J. Label Compd. Radiopharm 2015, 58 7–13
B. Schäfer et al.N-hydroxysuccinimide ester in DMF resulted in 5. This maleimide
serves as a possible protein conjugation function in biological
applications. In order to avoid the addition of nucleophiles to
the maleimide of 5, an aniline and an alkyl-hydrazine—both are
less basic than primary amines—were used to introduce the
ﬂuorescein and the tritium label, respectively. In a preliminary
study, it turned out that the aniline moiety of 5-aminoﬂuorescein
did not react with the Michael acceptor of N-(2-maleimidoethyl)-
2-aminopent-4-ynamide under the coupling condition applied
for the preparation of 6. Then, the ﬂuorescent anchor 6 was
obtained by coupling of the carboxyl group of 5 with 5-
aminoﬂuorescein in the presence of the coupling agent HATU.
The NMR structure investigation revealed that 5-
aminoﬂuorescein was conjugated to the carboxylic function of 5.
Based on earlier observations on isotopomer radioligands,21–23
the tritium label was introduced via an aliphatic compound
instead of aniline to increase the radiolytic stability of the
labelled anchor molecule. N-Aminopiperidine was chosen for
that purpose, because it is less basic than cyclohexylamine,24,25
and after N-acylation, it results in stable hydrazides. Coupling
of tritium labelled N-aminopiperidine to the carboxylic acid
function of 5 results in an anchor molecule possessing a
headgroup homologous to that of 6, and this way, theScheme 2. Preparation of [
3
H]N-aminopiperidine: (a) Pd/C (10% Pd),
2
H2 (1) or
3
H2
(2), EtOAc, RT, 3 h; (b) KNO2, 1 M HCl, 0 °C, 2 h; (c) LiAlH4, THF, Ar atm, 60 °C, 3.5 h.
Figure 1. ESI mass spectrum of [
2
H]piperidine and the abundance of the
isotopologues;
a
measured intensity,
b
relative intensity corrected with the natural
abundance of
2
H,
13
C.
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11nonspeciﬁc tritium incorporation into the cholesterol moiety or
into the headgroup is not feasible. Before preparing the tritium
labelled anchor by N-acylation of [3H]N-aminopiperidine with 5,
the unlabelled isotopologue 7 was prepared in order to optimize
the reaction conditions and carry out NMR measurements. For
the preparation of the tritium labelled N-aminopiperidine,
4-bromopiperidine was considered as a precursor in a deuterium
labelling experiment (Scheme 2). The 4-bromopiperidine base
was liberated from the hydrobromide salt, and it was reduced
with deuterium gas in the presence of Pd/C (10% Pd) catalyst.
The resulting [2H]piperidine hydrochloride was analysed by
TLC and ESI-MS. The separation of 4-bromopiperidine and
piperidine was achieved on silica gel 60 F254 glass plates in
n-BuOH–AcOH–H2O 2:1:1, as their Rf values were found to be
0.48 and 0.38, respectively. The TLC analysis of the crude [2H]
piperidine hydrochloride revealed that the conversion of
4-bromopiperidine was complete. Furthermore, the deuterium
incorporation level was estimated by an ESI-MS analysis. It
was found that 0.9 deuterium atoms/piperidine molecules were
incorporated on average, but isotopologous species containing
two or three deuterium atoms were also identiﬁed (Figure 1).
These results suggested that this precursor is satisfactory for
achieving an approximate molar activity of 1 TBq/mmol. In
the next step, [3H]N-amino-piperidine was prepared from
4-bromopiperidine (Scheme 2). Reduction of the brominated
piperidine with tritium gas in the presence of Pd/C (10% Pd)
catalyst resulted in tritium labelled piperidine that was
nitrosated. The resulting [3H]N-nitrosopiperidine was then
reduced with LiAlH4, and [
3H]N-aminopiperidine was isolated
as a hydrochloride salt. The carboxylic acid 5 was activated
with HOBt in the presence of DIC, and the resulting active ester
was used in situ for the N-acylation of [3H]N-aminopiperidine to
give the tritium labelled anchor 8. HPLC analysis revealed that
a signiﬁcant amount of tritium labelled N-aminopiperidine
was coupled to 5 (Figure 2). The puriﬁcation of the crude
cholesterol derivative was achieved by RP-HPLC, resulting in
17.4MBq of pure 8 with an isolated radiochemical yield of
17%. The sterical hindrance of the carboxylic acid function of
5 and the more diluted reaction mixture as compared with that
of 6 and 7 resulted in the low yield of 8. Quantitative analysis
of the concentration and radioactivity of the labelled anchor 8
was performed by RP-HPLC via UV and radioactivity detection
using a calibration curve made by 7. The speciﬁc activity of
the tritiated cholesterol anchor 8was found to be 1.37 TBq/mmol
that is higher than the theoretical value. Beyond tritium
substitution of Br in 4-bromopiperidine, catalytic 1H/3H exchange
reactions also took place presumably at positions 2 and 6 of the
piperidine ring. When 2–3 h of reaction time is applied for
catalytic dehalotritiation, the catalytic exchange becomes
signiﬁcant and increases the speciﬁc activity.23 The ESI-MS
analysis of the deuterium labelled piperidine also indicated
catalytic exchange reactions. It is important to note that the
convergent synthetic strategy ensures that all the tritium atoms
are localized in the piperidine ring of the headgroup, because
after the tritium gas reduction of 4-bromopiperidine, further
transformations do not affect the tritium distribution.
The control compound 6, a ﬂuorescent GPI anchor mimetic,
was used to assess the membrane association property of the
designed [3H]anchor. The solubility of 6 was investigated in an
aqueous medium before the imaging application. It was found
that the amphiphile 6 partially dissolved in a serum-free medium
as micellar associates and the remaining portion formedwww.jlcr.orgWiley & Sons, Ltd.
Figure 2. Radio-HPLC chromatogram of (a) the crude and (b) the puriﬁed tritium labelled cholesterol anchor 8. [
3
H]N-aminopiperidine was eluted without retention, and
8 was eluted at tR = 6.90 min.
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12precipitates. The resulting heterogeneous mixture was
incubated with 10 eq β-cyclodextrin that forms water-soluble
inclusion complexes with cholesterol and 3β-hydroxyl-modiﬁed
cholesterol derivatives.26 This way, 0.5mM aqueous solution of
the cholesterol amphiphile was prepared. Then, SH-SY5Y cells
were treated with 1μM of the inclusion complex of 6 for
30min. After delivering to live SH-SY5Y cells, an intensive
membrane staining was observed, that is, 6 incorporated into
the cell membrane similarly to our original anchor18 (Figure 3).
It indicates that a slight modiﬁcation in the α-amino acid
function of the headgroup is tolerated with the retention of
the membrane association properties. The tritium labelled
anchor 8 could also be solubilized in cell culture medium withFigure 3. Confocal laser scanning (left) and differential interference contrast (right) m
followed by a treatment with the nuclear dye DRAQ5 for 5 min at 37 °C. On the image
wileyonlinelibrary.com/journal/jlcr.
www.jlcr.org Copyright © 2015 Johthis method, and it was applied for studying the cell membrane
incorporation of 8. SH-SY5Y cells were incubated with 1–100 nM
of 8 or 2 at 37 °C for 10 and 30min, and then cells were washed
and trypsinized. The membrane incorporated radioactivity was
determined by liquid scintillation counting of the ﬁltered cells.
It was found that 2 was not incorporated into the cell
membranes, as the radioactivity of these cell population was
slightly above the background (Figure 4). However, when cells
were treated with 8, concentration- and time-dependent
incorporation of the radioactive cholesterol anchor was
observed. The radioactivity of the cell cultures was ca. 20%
higher after 30min incubation than after 10min incubation,
indicating fast plasma membrane incorporation of 8.icroscopy of SH-SY5Y cells after 30 min incubation with 1 μM cholesterol anchor 6
, ﬂuorescein is green and nuclei are blue. This ﬁgure is available in colour online at
n Wiley & Sons, Ltd. J. Label Compd. Radiopharm 2015, 58 7–13
Figure 4. Incorporation of the [
3
H]cholesterol anchor 8 to the membrane of SH-
SY5Y cells. Cells were incubated with different concentrations of 2 (grey bars) or
8 (black bars) in the presence of 10 μM β-cyclodextrin followed by liquid
scintillation counting of the washed and trypsinized cells. The error bars represent
SEM values of three parallel measurements.
B. Schäfer et al.Conclusions
Semisynthetic lipoproteins prepared from recombinant proteins
and designed lipid derivatives are valuable probes of the
membrane-associated lipoproteins. In this article, we reported
the synthesis of a novel tritium labelled cholesterol anchor that
contains the radioactive label in the headgroup. It was achieved
in a convergent synthetic approach by the acylation of [3H]N-
aminopiperidine with the 1-hydroxybenzotriazole ester of the
carboxylic acid derivative 5. This structure of the headgroup
features the introduction of the tritium label into the same
position where a ﬂuorophore was introduced in 6. Thus, the
ﬂuorescein and tritium labelled anchors are constitutionally
related, and the ﬂuorescence microscopic images are relevant
to the [3H]cholesterol incorporation data. Each synthetic step
was optimized by using unlabelled standard compounds and
by tracer experiments, and ﬁnally, the target cholesterol
amphiphile 8 was obtained with a radiochemical purity of 98%
and with a chemical purity of 99%. It was demonstrated that
the membrane incorporation of the resulting headgroup labelled
[3H]cholesterol anchor is concentration and time dependent, and
that it can be investigated at low concentrations, below the
working concentration of ﬂuorescent analogues. It is advantageous
because under these conditions, the exogenous introduction of
cholesterol derivative 8 results in low membrane concentration
and thus low level of membrane perturbation, cellular stress.
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